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Abstract 
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Pharmaceutical expenditures are an important part of the entire hospital operating budget, 
and inpatient pharmaceuticals denote one of the highest costs in hospital care.  Predictions for 
medication budgets based on the types of patients have been largely undertaken in medical 
hospitals and not psychiatric facilities.  According to several previous studies, gender, age, 
diagnosis, comorbidity and length of stay (LOS) affect the general inpatient treatment 
expenditures.  However, whether or not the impact of these factors differs in psychiatric hospitals 
remains to be investigated.  To that end, the current study examines medication costs for  mental 
and behavioral health disorder as well as the primary chronic diseases commonly comorbid with 
mental and behavioral health disorders that suggest formulary management control might be 
helpful.  Multiple regression models were developed to determine the leading drivers associated 
with the growing inpatient hospital medication costs among patients admitted to an acute 
psychiatric hospital.  We also analyzed LOS using a Poisson model in order to determine 
whether it is a proxy for psychiatric inpatient medication costs.   
Our finding selected 51 medications (14% of the 364 total medications consumed 90% of 
the total medication cost) under A category (AV, AE, and AN) and B category (BV, BE, and 
BN) in order to develop a medication list (MUC, medication under control) that suggested cost 
control measures based on cost and clinical criticality could be important.  This study 
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demonstrated that comorbidity, principal and secondary diagnoses, LOS, and MUC are 
associated with higher inpatient medication costs than other factors, including age, gender, 
insurance type, and month admitted.  Our study also observed that the principal ICD-10-CM 
codes F10 (Alcohol related disorders) is associated with high inpatient medication cost.  
Secondary diagnosis related groups (DRGs) 203 (Bronchitis & asthma), 192 (Chronic 
obstructive pulmonary disease, COPD), 201 (pneumothorax), 639 (Diabetes), 642 (Inborn and 
other disorders of metabolism), 645 (Endocrine disorders), 641 (Nutritional & miscellaneous 
metabolic disorders), 690 (Kidney & urinary tract infections), 675 (Other kidney & urinary tract 
procedures), 699 (Other kidney & urinary tract diagnoses), and 700 (Other kidney and urinary 
tract diagnoses), 305 (Hypertension), 310 (Cardiac arrhythmia & conduction disorders), 303 
(Atherosclerosis), 293 (Heart failure & shock), and 316 (Other circulatory system diagnoses) 
were found to be associated with higher inpatient medication costs.  In addition, LOS can be 
used as an indicator (proxy) for inpatient medication cost when patients present with a secondary 
DRG 639 (diabetes) and 690 (kidney & urinary tract infections) in an acute psychiatric hospital. 
Viewed collectively, this study would enable executives of acute psychiatric hospitals to 
identify the most important factors that are associated with high inpatient medication costs, 
thereby assisting in the development of the hospital pharmaceutical budget using a novel and 
scientific approach. 
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CHAPTER 1: INTRODUCTION 
1.1  Background 
 
The ever-increasing number of patients with mental disorders, and the concomitant 
increasing occurrence of chronic diseases have significantly increased healthcare expenditures 
over the past decade.  Among hospital stays related to mental health and substance abuse, 
schizophrenia, mood disorders, depression, and bipolar disorder had the highest discharges in 
2014 [1].  By 2016, 8.6 million inpatient stays were involved with at least one mental disorder or 
substance use disorder diagnosis, thereby accounting for 32% of the total inpatient stays [2].  
Medication expenditures contribute a high portion of the overall hospital operating budget, and 
inpatient medications represent one of the highest expenditures in hospitals [3]. Between 2013 
and 2015, the costs of inpatient pharmaceutical increased 23.4% on average annually.  The 
increase in expenditures for inpatient medications surpassed the increase in spending on retail 
medications, which only grew by approximately 10% [4].  A survey conducted in 2017 from a 
healthcare industry group revealed that 96% of healthcare executives reported significant growth 
in inpatient medications costs over the past five years.  Along with mounting prescription rates as 
a leading driver of budget increases (95% of surveyed organizations or institutions reported), 
followed by increased use of specialty medications (91%) and increased patient acuity (64%), it 
can be inferred that the cost of prescription  medications assume significance in the context of 
the United States market, surpassing other healthcare sectors [5].  By 2020, medication 
expenditures are expected to account for 11.1% of the total national health expenditures [6-8].  
Moreover, the three most common strategies that hospital leaders used to manage growing 
medication expenditures were increased use of generic medications (89%), tightening up the 
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hospital's medication formulary (82%), as well as asking pharmacists to identify expensive 
medication use patterns and to suggest alternative medication treatments (75%) [9].   
In fact, the data from hospital pharmacies are powerful tools that can help reduce 
medication-related expenditures.  In addition to medication costs, evaluating other healthcare 
data may help identify the causes of mounting medication expenditures today.  As opposed to 
investigating only medication costs per patient, evaluating medication cost per diagnosis-related 
group (DRG), may be able to align expense analysis by reimbursement groups.  In addition, 
evaluating the length of stay (LOS), and other similar measures that reflect overall medication 
costs may be helpful.  For this reason, identifying medication cost savings through utilization-
based data may be helpful.  Although medication cost containment has gradually spread across 
most hospitals in the United States, only 29% of hospitals monitor formulary compliance, which 
can lead to inefficiencies in medication utilization.  Analyzing medication use patterns, ensuring 
proper management of the medication formulary, identifying top medication cost drivers, as well 
as forecasting medication expenditures may be useful methods of controlling hospital medication 
costs [10].  
 
1.1.1 Inpatient Medication Cost 
 
During a hospitalization, medications including antidepressants, anti-anxiety medications, 
anxiolytics, stimulants, mood stabilizers, and antipsychotics play a pivotal and potentially life-
altering role in treating patients presenting with a variety of mental disorders.  With constant 
growth in the usage of psychotropic medication, the medication expenditures for these types of 
patients constitutes a significant portion of the psychiatric hospital operating budget [11].  Over 
nine-tenths of the surveyed general acute care hospitals reported that inpatient medication cost 
increases had a moderate to severe effect on their ability to control the budget.  However, 
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psychiatric hospitals were excluded from this survey, and similar studies have not been 
conducted in this setting.   
 
1.1.2 Hospital Reimbursement Systems 
Under existing reimbursement systems, hospitals are paid by government sponsored or 
private insurance companies.  Under certain scenarios, hospitals may be reimbursed less than the 
actual amount spent on treatment, particularly in bundled reimbursement systems.  Hospitals are 
required to develop plans to lower treatment costs in order to manage budgets.   In this context, 
Prospective Payment System (PPS) denotes a method whereby Medicare payment is made based 
on a predetermined, fixed amount that only focuses on the conditions being treated.  Under this 
model, the payment amount is derived based on the classification system of a particular service, 
such as diagnosis-related groups (DRGs) for inpatient hospital services [12].  In 2011, the 
Centers for Medicare and Medicaid Services (CMS) expanded this concept of “bundled 
payment” to provide incentives in order to enable a more efficient and high-quality healthcare 
delivery [13, 14].  Under bundled payment, patients are charged a flat fee for an inpatient DRG 
episode, regardless of the actual cost, which takes into consideration the frequency as well as 
variance of the episode (an episode of care is defined as a single stay in hospital) cost [15-17].  
When reimbursement rates fail to keep up with the input costs, such as medications, hospitals are 
compelled to assimilate a certain amount that remains uncovered [18].  Since the bundled 
payment is a fixed amount, hospitals will no longer bear the difference and can make a profit if 
costs such as those of medications can be reduced.  Therefore, serious attention must be paid to 
research-based and actionable efforts to contain inpatient pharmaceutical costs. 
A problem arises owing to the strong possibility that the cost of inpatient medications 
prescribed for mental/behavior disorders (MBDs) increases the hospital budget assigned to the 
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pharmacy department.  This, in turn, leads to an inevitable financial burden on acute psychiatric 
hospitals.  To this end, lowering inpatient medication costs, exploring the leading drivers of 
growing medication costs, and ameliorating the hospital’s financial burden are the most 
challenging facets of hospital pharmacy management, particularly in the context of mental and 
behavioral health treatment facilities.  Additionally, forecasting future medication cost trends for 
MBDs and chronic diseases, as well as monitoring and reacting to trends, is also a serious issue 
that merits attention. 
 
 
1.2  Review of Literature 
  
           The drivers of medication spending patterns are both diverse and complex.  From the 
hospital’s perspective, the most challenging task is to accurately estimate future expenditures for 
medications.  However, in order to attain this objective, the primary endeavor is to determine the 
most critical reasons for high medication expenditures in hospitals. 
Patients and market factors are random, inconsistent, and unpredictable factors.  In this 
regard, patient demographic factors (gender, age, etc.), and clinical factors, such as length of stay 
(LOS), diagnosis-related groups (DRGs), major diagnostic categories (MDC), comorbidities, 
etc., are not controllable factors.  Market factors, such as medication shortages and the 
emergence of innovative medications are also not amenable to change.  However, continuous 
monitoring of these factors is something that is indeed feasible. 
Although the aforementioned factors are uncontrollable, some solutions do exist that can 
help control costs through the implementation of  hospital control mechanisms.  These include 
periodic formulary reviews conducted by the hospital pharmacy and therapeutic (P&T) 
committee and regular medication usage education prepared for physicians.  Research has 
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demonstrated that educational interventions have been successfully implemented to improve 
prescribing competencies.  Within this context, the World Health Organization (WHO) Guide to 
Good Prescribing has credible evidence that supports its use as an encouraging model to design 
targeted prescription behaviors [19]. 
 
1.2.1 External Factors 
1.2.1.1 Inpatient medication utilization.  Uncontrollable demographic changes in the 
United States are an example of an external factor that has contributed to the rise in medication 
usage and costs.  More than 10,000 Americans above the age of 65 years enroll in the Medicare 
program every day.  Inexorably, this puts a tremendous strain on the entire system.  The Census 
Bureau forecasted the number of Americans aged 65 years and above will exceed the proportion 
of minors by 2030.  This means that one in five Americans will be a senior citizen for the first 
time in American history [20]. 
Such a large aging population is accompanied by a corresponding increase in chronic 
illness and disease.  This has further increased medication usage and cost    a higher order 
phenomenon that is beyond the control and management of pharmacy and hospital leaders [21].  
According to data published from the Healthcare Cost and Utilization Project (HCUP), many 
patients treated for issues related to mental health and substance abuse in United States hospitals 
seek recurring treatment.  The study published in 2014 showed that 12.8% of mental disorder 
discharges and 9.9% of substance abuse-related discharges were readmitted for the same type of 
diagnosis within a span of 30 days.[21, 22]  Therefore, it is evident that uncontrollable drivers, 
such as increased hospital stays attributed to an aging population, can lead to possible increases 
in inpatient medication cost.   
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1.2.1.2 Medication shortages.  The United States has been confronted with an 
increasingly serious problem of medication shortages over the past two decades, despite a 
functional warning system for impending products facing shortages [22].  It is notable, that 
medication shortages are not a new phenomenon and have led to difficulties for physicians, 
health care facilities, patients, and federal regulators [23].  Medication shortages are attributed to 
many reasons including manufacturing issues, regulatory problems, difficulties in acquiring raw 
materials, business decisions, as well as several other disturbances within the supply chain.  
Medication shortages adversely affect patient care by causing replacement of safe and effective 
therapies with substitute treatments, which may not be optimal.  Moreover, it also imposes a 
significant burden on providers and health care facilities [24].  In fact, most medication shortages 
observed in the United States involve generic medications [25], which are likely due to few 
financial incentives to produce off-patent medications from manufacturers [22].  
Findings from a  national survey conducted in 2017 suggested that vital medications 
which impacted many service lines were affected by medication shortages, including those for 
neurology (18%), allergy and asthma care (15%), psychiatry (10%), endocrinology (10%), and 
ophthalmology (5%) treatment [26].  
Medication shortage statistics show that there were 186 new shortages in 2018 including 
anesthetics, antibiotics, cancer drugs and much more.  As of June 2019, the top 5 drug classes 
with active shortages included antimicrobials, chemotherapy, cardiovascular, central nervous 
system, and electrolytes/nutrition/fluids.  Many of these are critical for patients with serious 
illnesses [27].  Much time and effort are spent in managing medication shortages, such as 
inventory tracking and seeking alternative supply chains.  More alarmingly, some vendors are 
involved in price gouging when selling medications in short supply to hospitals [28].  
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1.2.1.3 New and innovative medications.  Another largely inconsistent and 
uncontrollable external factor is an issue that is faced on a more practical level: the high cost of 
new and innovative medications.  The United States is the world’s leader in biopharmaceutical 
investment and innovation [29]. Although Americans have access to many of the most 
innovative medications worldwide, they are becoming increasingly difficult to afford.   
In 2015, a study conducted by Tufts Center for the Study of Drug Development 
announced it had calculated that it costs pharmaceutical companies $2.6 billion to develop a new 
medication    up from the $802 million the Center estimated in 2003 [30].  Meanwhile a survey 
on the research and development (R&D) costs of 106 new medications showed that the estimated 
average out-of-pocket cost per approved new medications is $1.39 billion.  The study also 
estimated an increase in post-approval R&D costs, bringing the total cost estimate to $2.87 
billion [31].  
An example pertinent to an acute psychiatric hospital would be valbenazine for tardive 
dyskinesia (TD)    a severe condition that can affect almost one out of four patients on previous 
or existing antipsychotic treatment,  which is inclusive of both first-generation antipsychotics 
(FGAs) and second-generation antipsychotics (SGAs) [32]. Although the prevalence is fewer 
than 200,000 per year in the United States, the cost of medication treatment is still high in terms 
of the monthly cost.  Depending on the wholesaler used, velbenazine imposes costs from $5,000 
to $6,000 per month, meaning that patients diagnosed with TD may demonstrate significantly 
higher healthcare utilization and costs [33].  
In May 2018, the Trump administration created the “American Patient First” blueprint in 
order to take a proactive step towards solving this problem.  As per the blueprint, the government 
will encourage greater competition between pharmaceutical companies and reduce the regulatory 
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burden.  This, in turn, will allow new medications to enter the market faster and at cheaper 
prices.  This blueprint will also remove large numbers of intermediaries, such as 
pharmacy benefit managers (PBM) and insurance companies.  Doing this will expedite the 
approval process for over-the-counter (OTC) drugs, thereby allowing patients to get cheaper 
options without a prescription.  In addition, the government will take drastic action to punish 
pharmaceutical manufacturers that use patent law in order to stifle competitors, especially for 
generic medications [34, 35] [36].  
1.2.1.4 Patient factors.  Patients in a psychiatric hospital with additional medical 
conditions may incur higher costs for their medications.  Equally, psychiatric hospitals are also 
required to treat the medical conditions the patient also suffers from.  Arthritis, as a chronic 
condition, as well as depression, as a mental health illness, are both perceived to be some of the 
leading causes of disability worldwide [37, 38].  To illustrate, a patient with severe rheumatoid 
arthritis may be on an immunomodulatory treatment that is necessary, but also very expensive.  
Many other linkages have been found to exist between mental illness and cardiovascular 
diseases, in addition to diabetes, obesity, asthma [39].  
Patients - Psychotropic medication and mental disorders.  The 2015 National Survey on 
Drug Use and Health (NSDUH) observed that approximately 43.4 million adults (18% of the 
population) in the United States have suffered from some kind of mental illness in the past year 
(including mental, behavioral, or emotional disorders, but excluding developmental and 
substance use disorders) [40].  The latest self-report study published in 2017 shows that 1 in 6 
U.S.  adults reported taking psychotropic medications on at least one occasion.  However, these 
numbers may have been underestimated because the prescriptions were self-reported, and the 
estimates of long-term use were confined to a single survey year [3, 41] [42].  Meanwhile 
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antidepressants are the most frequently prescribed medications for treating depression, anxiety 
and other MBDs [25].  In 2005, antidepressants surpassed antihypertensive agents to become the 
most commonly prescribed class of medications in office-based and hospital outpatient–
based medical practices [43, 44].  The data for antidepressants used in inpatient settings are 
rarely reported.  From 1999 to 2010, a significant growth was reported in the long-term use of 
antidepressant medications in the United States, which may explain the overall increasing trend 
in use [45].  Individuals treated with antidepressants with inadequate responses, became more 
likely to receive additional treatment with more costly antipsychotic medications which 
increased treatment costs [46].  However, there are very few reports for inpatient-based 
psychotropic medication use patterns as well as cost data published during the past decade 
among adults in the United States.   
Patient gender.  The 2014 NSDUH survey results indicated that mental illness was more 
prevalent among women (21.2%) as compared to men (14.3%).  In addition, this study observed 
that when compared to men, women were 50% to 70% more likely to be diagnosed with major 
depression (43.2% vs. 27.2%, p < 0.001) or anxiety disorders (41.8% vs. 24.4%, p < 0.001) [40].   
Among previously published studies on the age and gender patterns of antipsychotic use, 
women between the ages of 25 and 84 years had recorded a high rate of use as compared to men 
in the same age range [25].  Furthermore, the Intercontinental Marketing Services (IMS) data 
showed that anxiolytics were also proportionately more commonly prescribed to antipsychotic-
treated women in comparison to men.  Similarly, other studies also suggest that women are 2.5 
times more likely to take antidepressants than men and that almost a quarter of women between 
40 and 59 take antidepressants, more than in any other age-gender group [47].  Although the 
prevalence of social anxiety is found to be equal in both men and women, the lifelong diagnostic 
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rate for anxiety is found to be higher in women in comparison to men.  Additionally, women 
suffering from a lifetime diagnosis of one type of anxiety disorder were more likely to be 
diagnosed with an additional anxiety disorder than men [48-50].  For this reason, women are 
more likely to receive two or more classes of psychiatric medications than men, which increases 
medication-related expenses [51, 52].  
Evidence seems to suggest that there is a difference between men and women in terms of 
prevalence of mental illness and patterns relating to psychotropic medication usage.  It is 
important to note that gender may be one significant driver of rising medication costs in an acute 
psychiatric hospital.  Thus far, no research has been published to determine whether or not there 
is a linkage between the patient’s gender and the inpatient cost of medications for MBDs.  This 
association between gender and inpatient cost of psychotropic medications, as well as the 
medications for other chronic diseases, continues to be a subject that necessitates further 
research.   
Patient age.  Mental illness occurs among more than 20% of adults aged 18 to 49, and 
14% of the adults aged 50 and older, which is inclusive of Alzheimer’s disease.  Between 2008 
and 2015, the percentage of adults with any mental illness remained generally stable, with the 
highest prevalence among those who were aged 26 to 49, and the lowest among those aged 50 
and older, which included patients with Alzheimer’s disease [12].  Males and females aged 40 
and above were more likely to take antidepressants in comparison to patients belonging to other 
age groups [53].  It was found that the percentage of adults who were prescribed both 
antipsychotics and mood stabilizers tended to decline with age.  Similar declines with age were 
observed for antipsychotic-treated men and women who were prescribed two or three of the 
other psychotropic medication classes (antidepressant, anti-anxiety medication, and mood 
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stabilizer) [54].  Meanwhile a study carried out among psychotropic medication prescriptions 
suggested that antipsychotic use varies by patient age within a retail setting [55].  It was found 
that in two age groups namely, 18 to 39 and 40 to 64, affective psychoses (F39) and 
schizophrenia (F20) contributed nearly 70% of atypical antipsychotic usage.  By contrast, the 
two diagnoses represent only 41% of the usage among patients aged between 1 and 17, and 36% 
among patients whose age was at least 65 years.  For this reason, it is necessary to examine the 
relationship between the age of the patient and their medication use and cost within an acute 
psychiatric hospital setting. 
Patient medical insurance.  Medicare has been the most common payer for 
hospitalizations involving only MBD diagnoses (37% of aggregate hospital expenses).  On the 
other hand, Medicaid was found to be the most frequent payer for Substance Use Disorders 
(SUD) diagnoses only (29% of aggregate hospital expenses).  When viewed collectively, 
Medicaid was found to cover 56.0% of all inpatient stays with primary MBDs or SUDs, 
including those with co-occurring MBDs/SUDs.  However, Medicare accounted for the largest 
proportion (46%) of aggregate hospital costs [56].  More than 50% of all psychiatric 
hospitalizations were paid by Medicare or Medicaid, which may be linked to an individuals’ 
ability to maintain employment [57, 58].  The study that examined the costs/payments for 
psychiatric treatment (inpatient) in community hospitals suggested that the costs were 2.5 times 
higher as compared to the reported costs of the hospitals in delivering care.  It was found that the 
average cost for delivering care was the lowest for the uninsured and highest for Medicare: 
$5,707 for 7.4 days and $8,509 for 11.1 days, respectively for schizophrenia treatment; $4,356 
for 5.5 days and $7,593 for 9.4 days for bipolar disorder treatment; $6 $3,616 for 4.4 days 
and ,990 for 8.4 days for depression treatment; $3,422 for 3.7 days and $4,591 for 5.2 days for 
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medication use disorder treatment; and $4,147 for 3.8 days and $5,908 for 6.2 days for alcohol 
usage disorder treatment.  Therefore, understanding the relationship between insurance type and 
inpatient medication cost among psychiatric hospitals is worthy of exploration as one of the 
leading factors. 
Patient clinical factors – Comorbidity.  Patients are often comorbid for MBDs and 
chronic medical illnesses.  Nearly one out of four American adults aged 18 years and older suffer 
from a diagnosable mental disorder in a given year [59].  In 2009, 145 million people, which 
account for almost 50% of all Americans, were living with a chronic medical condition [60].  In 
2018, the Center for Disease Control and Prevention (CDC) indicated that six out of ten adults in 
the United States suffer from a chronic medical disease, and four out of ten have two or more, 
which contributed $3.3 trillion toward annual health care costs [61].  Investigators are yet to 
determine if having a chronic disease can increase the prevalence of depression or depression 
increases the risk of having a chronic medical disease.  Nevertheless, the linkage between mental 
health and chronic medical disease cannot be ignored.  Medication treatment for mental illness 
combined with chronic medical diseases may increase hospital medication expenditures [62-66].  
However, it is difficult to forecast when patients with both MBDs and chronic medical diseases 
will be admitted, which will make forecasting medication costs a very challenging task.   
Many associations have been found to exist between mental illness and cardiovascular 
diseases [53], as well as diabetes [67, 68], obesity [69, 70], asthma [71-73], and arthritis [74, 75] 
[76, 77].  A common research finding shows that patients who suffer from chronic diseases are 
more likely to also suffer from depression [59].   Depression is found to co-occur in 17% of 
cardiovascular cases, 23% of cerebrovascular cases, 27% of diabetes cases and more than 40% of 
individuals with cancer [78] [52] [79].  Depression, anxiety, impulsive eating disorders, as well 
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as substance use disorders were found to have significant associations with the subsequent 
diagnosis of hypertension [80].  In this regard, a study conducted in China showed that there is a 
linkage between anxiety and heightened risk of hypertension [81].  According to a systematic 
review, depression is a common phenomenon in patients suffering from  rheumatoid arthritis 
(RA) and is associated with poor prognosis [82].  In addition, higher rates of cardiovascular 
disease (CVD) and diabetes are also observed in patients suffering from schizophrenia.  In most 
nations, the standardized rate of mortality in schizophrenia is around 2.5, which results in a 
reduced life expectancy between 15 and 20 years.  To this end, CVD is a significant contributor 
of increased mortality in schizophrenia; it was found that mortality in schizophrenia ranged from 
40 to 50% with CVD in the majority of the studies [83].  
Since several studies have demonstrated a meaningful relationship between mental health 
and chronic diseases, it can be inferred that the medication treatment of mental illness combined 
with chronic diseases will greatly increase hospital medication spending [47-51].  Therefore, 
comorbidity is another factor that needs to be duly considered.  So far, few studies have 
considered this issue and did not break down the pharmaceutical expenses.   
Clinical factors involving MBDs.  Hospital care for patients with mental disorders in the 
United States has changed tremendously over the last several decades in the wake of numerous 
factors.  This includes the passage of the Social Security Act of 1965, which enacted the 
Medicare and Medicaid programs.  Notably, these programs made considerable progress in 
achieving parity in private insurance coverage for patients with mental disorders, creating 
competition within an increasingly specialized mental disorder workforce, as well as innovations 
in the services and treatment [84].  Since the mid-1960s, treatment for mental disorders has 
departed from a system characterized by care in state-owned facilities to one that is driven by 
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market forces.  Between 1971 and 2001, the share of spending on specialty mental disorder 
services dropped by nearly 70% for state mental hospitals; however, this expenditure on 
specialty mental disorder dropped by 65% for general hospitals and 366% with regard to private 
psychiatric hospitals [85-87].  Although many patients with mental disorders can be treated 
successfully in ambulatory care settings, inpatient treatment continues to be a key component of 
care [88].  The increasing number of hospitalized patients and longer hospital stays will lead to a 
continued increase in inpatient medication usage and cost.  Therefore, paying attention to the 
trends of use and costs of  medication prescribed in psychiatric hospitals can play an important 
role in controlling psychiatric hospital pharmacy budgets.  
Length of Stay (LOS).  LOS is one of the factors that contributes to rising pharmaceutical 
expenses across hospitals [89].  Among hospital stays related to MBDs and substance abuse, 
discharges were observed to be the highest for schizophrenia, mood disorders, depression, as 
well as bipolar disorder in 2014 [90] [91].  As noted earlier, 12.8% of mental disorder discharges 
and 9.9% of substance abuse-related discharges were readmitted for the same type of diagnosis 
within a period of 30 days [92].  
Length of Stay (LOS) as a proxy of inpatient medication cost.  Comorbidity is another 
key determinant of longer LOS.  A study conducted among coronary artery disease (CAD) 
patients with mental disorders showed that comorbid mental disorders are associated with higher 
healthcare utilization with regard to longer LOS and higher hospital readmission rates (RR) [93].  
Longer LOS and higher RR are also associated with mental disorders in patients admitted with 
myocardial infarction (MI) [94].  Also, patients with acute coronary syndrome (ACS) and 
depression were found to have longer LOS in emergency departments [95].   To that end, a study 
conducted in New Zealand showed that depression, as opposed to anxiety, is related to the 
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number and length of cardiac-related hospitalizations in patients with CAD [96].  A more recent 
study published in 2018 among readmitted patients showed that treatment-resistant bipolar 
disorder (BD) often accounts for longer hospitalization stays [97].  Atypical antipsychotics, 
anticonvulsants, antidepressants, and lifetime alcohol dependence predicted LOS for 68.2% of 
admissions for use (p = 0.042) [97].  
LOS with MBD/Substance Use Disorder (SUD).  Nationwide, in 2016, approximately 10 
million inpatient stays were found to involve at least one MBD or SUD diagnosis, which 
accounted for 27.8% of the total inpatient stays.  Among all MBD and SUD, depressive disorder, 
alcohol-related disorders, and schizophrenia were the most common primary diagnoses.  The 
average LOS for all MBD/SUD stays were higher as compared to all other stays (6.4 vs. 4.2 
days).  However, the average costs for MBD/SUD stays were found to be 50% lower than for all 
other stays ($7,100 vs. $11,500) [87].  This cost was not broken down to separate out the 
inpatient medication cost.  Therefore, LOS might be a feasible alternative indicator of the 
inpatient medication cost among MBD/SUD patients.   
 
1.2.2 Internal Factors 
Increasing medication expenditures are a financial burden on hospitals, patients and the 
government.  Notably, the factors affecting medication expenditures within the health system are 
usually determined by the scope and nature of the care provided.  To some extent, they can be 
controlled by the pharmacy manager.  One example is to replace expensive new medications 
with newly approved generics.  Such an approach is within the purview of pharmacy and 
therapeutics committees.  Although the current predicament of mounting medication 
expenditures cannot be addressed in a short span of time, the internal factors mentioned in the 
subsequent sub-sections can help control expenditure to some extent.    
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1.2.2.1 Hospital medication expenditure control strategies.  Although external factors 
such as inpatient medication utilization, medication shortages, patient clinical factors, new and 
innovative medications, comorbidity, patient medical insurance, patient age and patient gender 
are uncontrollable for medication costs in a hospital pharmacy, there is still a way to control 
costs by implementing hospital control mechanisms (C) and reviewing prescribing practices (D) 
(Figure 1.1).  Effective medication cost control strategies are known to vary in inpatient settings 
as compared to managed care and ambulatory care settings.  To that end, four primary factors 
drive growth in overall medication expenditures in the hospital setting: (1) high existing price of 
medications, (2) medication utilization, (3) rising costs of new medications, and (4) newly 
approved medications [98, 99] (Figure 1.2).  Rising medication costs pose a challenge for 
hospital budgets, insurance plans, and out-of-pocket spending for consumers.  Moreover, steeply 
rising medication prices are not a new predicament for hospital pharmacies, which have been 
making difficult formulary choices for several years [100].  
 
 
Figure 1.1  Factors impacting pharmaceuticals cost to hospitals. 
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 In most hospital pharmacy budgets, 20% of medications (high priority medications) 
typically account for 80% of hospital medication budgets.  Therefore, budgeting and cost-
containment efforts should ideally focus on those high cost medications, and cost-management 
plans should especially concentrate on those top medications for which prescribing patterns may 
be changed.  When medication cost growth in hospitals is attributed to increasing prices of 
medications, a cost-containment tactic could involve a change in a preferred formulary 
medication or a new therapeutic category to something less expensive yet as effective [101].  It 
has been found that it is possible to adopt an ABC-VEN matrix analysis in order to pinpoint 
medications demanding strict management control for effective utilization of hospital funds and 
reduction of out-of-stock situations in hospital pharmacies [102, 103].  ABC analysis combined 
with VEN analysis provides an organized common coding of potentially cost-effective 
medications [104].  In addition, recent findings suggest that a relatively small number of 
medications account for most of the funds allocated by hospitals.  Moreover,  non-essential 
medications represent nearly 45% of studied items and account for around 26% of the total 
hospital funds [105]. However, ABC analysis, VEN analysis, and ABC-VEN matrix analyses are 
rarely applied to studies conducted in acute psychiatric hospitals among adults with MBD [106, 
107].  
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Figure 1.2  Four primary factors drive growth in overall medication expenditures in 
hospital setting. 
 
 
There is a  reasonable and applicable cost-containment opportunity in moderating the 
trend in increasing expenditures, which means mitigating the rate of increase for high-priority 
medications.  Moderating the growing trend and avoiding unnecessary cost is as relevant as 
actual cost reduction.  A large number of studies and data demonstrated that hospitals bear heavy 
financial burdens from high-cost medications [108-110].  To that end, one study suggested that 
reducing high-volume medications could be more effective in optimizing the hospital medication 
budget than concentrating solely on reducing high-cost medications.[111]  Medications with high 
volume in the acute psychiatric hospital have been examined to determine whether strict 
medication management control can be useful.  These findings are important in the context of 
this study which aims to fill the gap in extant literature on examining LOS as a predictor as well 
as outcome variable.   
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On a related note, a systematic study needs to be conducted in order to fill the research 
gap in examining how factors such as age, gender, length of stay, DRGs (MBDs and chronic 
diseases), insurance, and comorbidity can influence inpatient prescription medication costs.  By 
combining all patient factors impacting inpatient psychotropic medication usage patterns and 
cost, an important task of the current study is to develop a regression model that can determine 
the most important drivers of medication costs to hospitals and how a hospital can monitor and 
react to changing trends.   
1.2.2.2 Physicians.  Personal experience, government regulatory approval, and guidelines 
are the three main factors guiding clinicians’ decision-making regarding treatment of psychiatric 
diseases, which inevitably involves prescription of psychotropic medications, the 
affordability/lack thereof could be a key factor in determining health outcomes for patients.  
Among them, personal experience is the key factor guiding clinical decision-making.  For 
example, most psychiatrists use second-generation oral antipsychotics (SGAs), in the treatment 
of schizophrenia, and they are costly.  Meanwhile long-acting injectable (LAI) SGAs were 
prescribed to one-third of schizophrenic patients.  It was found that the psychiatrists following 
the higher percentage of schizophrenic patients were associated with a higher use of LAI 
antipsychotics and a lower use of oral SGAs [112].  Thus, the discernment of physicians can help 
determine the cost of psychotropic medications that for patients and shape prescription decisions.   
 This was confirmed by a survey which found that 88% of physicians believe the cost of 
medications is an important consideration in the prescribing decision, and 71% are willing to 
sacrifice some extent of efficacy in order to make medications more affordable for patients.  
However, 80% of physicians are unaware of the actual medication costs; only 13% had been 
formally educated about medication costs [113].  Since a sizeable portion of physicians feel that 
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medication cost is an important issue for the patient, there is a strong possibility that physicians 
can prescribe less expensive medications with equivalent efficacy.  Hence, the prescribing 
decision of a physician can play a very critical role in containing hospital inpatient medication 
costs. 
1.2.2.3 Pharmacy and therapeutic (P&T) committee and formulary management 
issues.  The Pharmacy and Therapeutics (P&T) Committee typically oversees the various facets 
of medication therapy in an institution.  More specifically, they are required to ascertain the costs 
benefits of all medications and determine the ones that have the greatest efficacy per dollar.  
Furthermore, P&T committees adopt an evidence-driven strategy to effect changes in the health 
systems through re-evaluation of existing policies and an emphasis on latest research to support 
decision-making.  It is comprised of actively practicing physicians, other prescribers, 
pharmacists, nurses, administrators, quality-improvement managers, and other health care 
professionals who participate in the medication-use process [114].  
To be an efficient and successful P&T committee, it is important to generate a timeline 
for formulary reviews to set periodical expectations, as well as a process for formulary requests.  
Also, collaboration with hospitals that fall under and comply with drug-prescription related 
practices under a single cohesive system can potentially help facilitate successful formulary 
standardization.  When developing a P&T committee or standardizing a formulary system, 
evidence-based data and rationales need to be provided to all departments in the hospital to 
support formulary changes [115].   
In the field of medical management, it is becoming increasingly evident that robust 
executive practice is crucial for effective delivery of inpatient care.  Hospital pharmacies deliver 
significant supportive services that embrace planning, designing, and organization, leading to 
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proficient clinical and administrative services.  The endeavor to contain costs with improved 
efficiency requires adopting a scientific method for undertaking hospital medication inventory 
management in order to attain better outcomes for the stated purpose (cost containment) [116].  
ABC analysis and VEN Analysis have been used successfully to narrow down the group of 
medications that require strict monitoring and facilitate optimization of medication formularies 
[102, 104, 105, 117-119].   
In most hospital pharmacy budgets, 10 – 20% of medications (high cost) account for 80% 
of hospital medication budgets.  Budgeting and cost-containment efforts should focus on those 
medications, and the cost-management plan should concentrate on those top medications for 
which changes in prescribing patterns can be realistic.   
1.2.2.4 Generic products.  For economic reasons, substituting brand medications with 
generic medications is common and encouraged.  Using alternatives are based on the concept of 
bioequivalence, which deemed equal to therapeutic equivalence.  Brand medications require 
long-term research and testing that take substantial investments, but generic medications only 
need to be shown to be bioequivalent to the brand product saving research expenditures and 
reducing purchase costs.  Therapeutic equivalence has been challenged for certain psychotropic 
medications by case reports and retrospective studies [120].  However, a study conducted among 
patients taking risperidone found no difference in the use of healthcare services between 
switchers and non-switchers of the brand versus the generic group [121].   
By understanding the external and internal drivers of health spending, researchers can 
analyze specific utilization patterns and expenditures of medication in order to develop a robust 
and accurate budget forecast. 
 37 
1.2.3 Important Drivers for Psychiatric Hospitals 
1.2.3.1 Newly approved psychiatric medications.  Since the year 2015 prices of 
newly approved psychiatric medications have risen drastically.  It is a known fact that 
new psychiatric medications are often very expensive [122].  For example, injectable 
Invega Sustenna costs roughly $1,500 per injection.  In 2015, there were three new 
psychiatric medications approved by the FDA, which are Aristada, an extended-release 
injectable medication that is for treatment of schizophrenia; Rexulti, once daily oral for 
the treatment of depression and schizophrenia; and Vraylar, a once-daily oral medication 
for the treatment of schizophrenia and bipolar disorder.   
In 2016, no new medications were approved in psychiatry, but two new medications for 
neurology were approved.  Briviact was approved for the treatment of partial onset seizures 
related to epilepsy.  Carnexiv was approved for replacement therapy when oral administration is 
not feasible for adults with seizures. 
In 2017, Austedo and Ingrezza were approved for the treatment of tardive dyskinesia, and 
in July 2018, Perseris, a once-monthly extended-release injectable was approved for treatment of 
schizophrenia in adults. 
In 2019, Spravato (esketamine), a nasal spray has been approved for treatment of 
resistant depression in adults; Zulresso (brexanolone) was approved for the treatment of 
postpartum depression. 
Over the past five years, an average of two new medications were approved on a yearly 
basis for patients with MBD (including 2018).  In addition, a large number of new medications 
for other chronic medical conditions annually still imposes a burden on psychiatric hospitals.   
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1.2.3.2 Other medical conditions and medications.  Psychiatric hospitals are also 
tasked with treating any additional medical conditions the patient may have. Many such 
medications are new and only available as the brand name until they come off patent.  For 
instance, a psychiatric patient with severe rheumatoid arthritis may be on an immunomodulatory 
medication, which is needed, but also very expensive.   In 2017, Zilretta (triamcinolone 
acetonide extended-release injectable suspension), an extended-release injectable suspension, 
was approved by the FDA for the treatment of osteoarthritic knee pain.  More examples of new 
medications for the treatment of chronic diseases are also emerging [123].  Over the past five 
years, fifteen new medications were approved for diabetes, three medications for asthma, two 
medications for hypertension, one for the treatment of chronic obstructive pulmonary disease 
(COPD), and one for high cholesterol.  Similarly, the FDA approved three new medications for 
cardiovascular abnormalities over the past three years.  New medications such as these can add 
significantly to the pharmacy budget. 
           Due to the significant association between MBD and chronic diseases, medication 
treatment of mental illness combined with chronic diseases, may dramatically impact hospital 
medication expenditures.  Therefore, comorbid conditions requiring expensive medications may 
significantly impact the medication budget.  However, there is no plausible way to predict when 
one of these patients with comorbidities will be admitted.  This uncertainly makes forecasting 
very challenging.   
 
1.3  Research Objective 
In order to expand the empirical research examining the association between high 
inpatient medication cost in psychiatric hospitals and its leading factors, ABC-VEN matrix 
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analysis was conducted as a preliminary study to examine mental and behavioral health disorder 
medications and the primary chronic disease medications associated with mental and behavioral 
health disorders that demand strict formulary management control.  In chapter 3, multiple 
regression models were designed and analyzed to determine the leading drivers associated with 
growing inpatient hospital medication costs among patients admitted to a mental and behavioral 
health disorder hospital. One primary focus of the chapter was to determine if secondary major 
diagnoses codes (SMDC) had a significant impact on inpatient medication costs and if they did, 
which specific SMDC had an impact.  Moreover, length of stay (LOS) was used as a proxy for 
inpatient medication cost allowing the use of count data regression models, like Poisson and 
Negative Binomial, to be analyzed.  
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CHAPTER 2: MEDICATION FORMULARY MANAGEMENT STUDY 
 
2.1  Introduction 
Cost containment has emerged as the most pertinent consideration when it comes to 
healthcare delivery.  It has been found that efficient management targeted on the accessibility 
and availability of essential drugs, along with alternative medications in pharmacy practice, are  
imperative [118, 124].  Hospital pharmacies deliver a very significant supportive service that 
includes designing, planning, and delivering the pharmaceutical services which leads to 
proficient clinical and administrative services [99].  Cost containment with improved efficiency 
requires addressing the needs of hospital drug inventory management using scientific methods 
for improved outcomes.  A variety of tools have been utilized for inventory management; the 
combination of VEN analysis, ABC analysis, and ABC-VEN matrix analysis has been 
successfully approved in order to narrow down the group of drugs that require strict monitoring 
and  optimization of drug formulary.    
ABC analysis refers to a method to determine which drugs are classified into Class A 
items (10-20% of items account for approximately 70-80% of cumulative drug cost), Class B 
items (10-20% of items account for a further 15-20% of the cumulative drug cost) and Class C 
items (the remaining 60-80% of items explains 5-10% of the total drug cost).  When making 
drug selection and purchasing decisions, ABC analysis will be used to prioritize Class A items 
[116].  The result of drug selection (Class A items) provided an important platform to target the 
most expensive DRGs and ICD-10-CM codes (ICD, International Classification of Diseases; 
CM, Coordination and Maintenance Committee) after the commencement of study on the factors 
of excessive drug expenditure.  However, ABC analysis of our fundamental study has certain 
limitations.  It is based solely on the rate of consumption and the monetary value of the item.  An 
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item of low cost and consumption does not mean that the item is not important or even lifesaving 
in an acute psychiatric hospital.  Their importance cannot be ignored simply because they are 
excluded from the list under category A [117].  In light of this situation, another tool involved in 
inventory management was introduced to our study, namely, VEN analysis. 
The drugs, in consonance with certain standards, can be classified into three categories: 
V, E, and N.  Vital medicines (V) are indispensable in saving the lives or the provision of basic 
health care, such as fluoxetine 10mg; essential medicines (E) are effective for less severe but 
important diseases.  They provide substitutes for vital products, such as imipramine 10mg; 
necessary medicines (N) meanwhile are also known as non-essential for minor or self-limiting 
diseases, such as loratadine 10mg.  The drugs in this category have a relatively high cost for 
additional therapeutic value.   In the hospital pharmacy management, VEN analysis is adopted to 
identify the most consumed and the largest number of therapeutic drugs, as well as to identify 
drugs that are over-consumed or inconsistent use with regard to the number of cases.  
Historically, it has been found that VEN analysis can be combined with the ABC analysis to 
discuss the removal of the "N" class of drugs from the high cost / high consumption of "A" 
resulting from the ABC analysis.   
ABC-VEN matrix analysis takes the two aforementioned analyses into consideration, 
ensuring that the result is not only based on economic value, but also on the clinical value [105].  
In addition, it gives us a clear picture of the classified drugs in accordance with the priority of 
their control mechanisms.  The resulting ABC-VEN matrix analysis can help ensure the 
complete and successful selection of high-cost drugs.  Furthermore, it provides a ‘double 
guarantee’ to target the most expensive DRGs and ICD-10-CM codes after starting the study on 
the factors of excessive drug expenditure. 
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In our study, we examined/identified the MBD medications and associated chronic 
disease medications prescribed in an acute psychiatric hospital that may benefit from strict 
formulary management control by conducting ABC analysis, VEN analysis, as well as ABC-
VEN matrix analysis. 
 
2.2  Study Design and Methodology 
Medication usage aggregate data sources, including procurement records, warehouse 
medicine records, pharmacy stock and dispensing records, adverse drug reaction (ADR), 
medication error reports, as well as patient medical records have been used [125].  In the current 
study, patient data were collected during a continuous time period by using patient medical 
records (coding and summary reports).  These expensive medications can be highlighted through 
aggregate data analysis on medicine usage and expenditure. 
This study was conducted in a 35-bed, licensed, not-for-profit acute psychiatric hospital.  
In this regard, all admitted patients  diagnosed with psychiatric and chemical dependency 
disorders were provided with comprehensive behavioral health services.  The consumption data 
were retrieved from the Coding and Summary Report of 400 patients.  These patients were 
enrolled between March 16th and July 27th, 2018 thus collecting approximately 4-month 
medication consumption data.  Among the 400 patients, six patients did not take any medication 
during the hospitalization, whereas three patients’ data could not be tracked during the study 
period because of incomplete records.  Therefore, a total of nine patients were excluded from 
ABC analysis, VEN analysis, and ABC-VEN Matrix analysis. 
For each patient the individual drug list with an exact item quantity during hospitalization 
was created and stored in the Excel sheet.  Subsequently, inpatient drug cost data were retrieved 
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from McKESSON Purchasing Detail Reports for the hospital.  Drug cost data were collected 
with the assistance of the inpatient pharmacist in the acute psychiatric hospital (McKESSON 
Report data selection: 11/01/2017 to 03/31/2018).     
The drug prices recorded in McKESSON purchasing report displayed the price per item 
(for example: acyclovir 800mg tab, 100 tablets).  The price per bottle is $50.19, and per tablet is 
$0.50) or package (for example: fentanyl 12mcg/hr).  For five patches, the package price is 
$60.57 and per patch is $12.11.  It was found in the McKESSON purchasing report that a drug 
with a certain dosage came at more than one price.  To illustrate: clonazepam 0.5mg tab (100 
tablets) contains three different prices: $1.30 per 100 tabs ($0.013 per tab), $4.05 per 100 tabs 
($0.041 per tab), and $3.90 per 100 tabs ($0.039 per tab).  Accordingly, the final price per 
clonazepam 0.5mg tab, $0.03, was calculated by taking the average of the three prices shown in 
the parentheses for further analysis.  During the four-month period, the total drug consumption 
quantity of clonazepam 0.5mg tab was 107 tablets.  Therefore, the single unit and total cost of 
this drug are $0.03 (price per unit) and $3.21 ($0.03*107=$3.21, price per drug), respectively.   
These data were then used for further study by implementing ABC analysis, VEN analysis, and 
ABC-VEN matrix analysis. 
A drug cost per patient Excel sheet and total drug cost Excel sheet were created in order 
to obtain and analyze the inpatient drug costs of each patient’s hospitalization during the study 
period.  Drug cost per patient was calculated by multiplying the cost per tablet, capsule, patch, 
etc. with the quantity of those that were consumed by each patient.  For another data set, total 
drug cost was obtained by integrating the drug cost per patient into an all-inclusive drug 
consumption and cost data, which includes complete drug items consumed by 391 patients, cost 
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per tablet, capsule, or patch, etc.  as well as quantity of those for each drug item along with the 
total drug cost of all drugs during the four-month study period. 
 
2.2.1 ABC Analysis   
ABC analysis can be applied to patient drug consumption or drug purchase data over a 
one-year period or shorter [125].  In this study, a total of 364 medication items (27678 
medication units) used for inpatient treatment in the acute psychiatric hospital (during the four-
month study period) were arranged in descending order in accordance with the total drug 
expenditure and cumulative expenditure for each item.  Furthermore, the cumulative percentage 
of items and cumulative percentage of expenditures (4 months) were calculated.  Next, the drug 
items were divided into three categories based on the cumulative cost percentage: Class A 
(72%), Class B (18%), and Class C (10%).   
 
2.2.2 VEN Analysis   
The VEN analysis of all 4-month drug items used for inpatient treatment was conducted 
by classifying all items into vital (V), essential (E), and non-essential (N) categories.  The VEN 
drug list was developed by a clinical pharmacist and a clinical psychopharmacology consultant 
with expertise in medically treating patients presenting with mental and behavioral disorders.  
The VEN drug list was created on the basis of criticality in line with the World Health 
Organization (WHO) lists of essential medicines (2017) [126] and VEN category assignment 
criteria [125], before being finalized with justification by the inpatient pharmacist.   
 
2.2.3 ABC-VEN Matrix Analysis  
ABC-VEN matrix analysis was implemented by generating a crosstab of two individual 
analyses.  After creating nine different subgroups, they were further divided into three different 
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categories: Ⅰ, Ⅱ, and Ⅲ (Table 2.1).  Category Ⅰ consists of sub-categories AV, AE, AN, BV and 
CV (The first letter indicates the position of the item in the ABC analysis, while the second letter 
indicates the position of the product in the VEN analysis).  Category Ⅱ consists of sub-categories 
BE, CE and BN and Category Ⅲ only contains sub-category CN.  The existence of statistically 
significant differences among nine different subgroup categories under all three classes was 
examined in order to confirm the significance of performing ABC-VEN matrix analysis.  In 
order to establish the foundation for the cost drivers regression analysis in Chapter 3, the 
difference in drug cost among nine different groups: AV, AE, AN, BV, BE, BN, CV, CE, and 
CN were also explored in this chapter. 
 
Table 2.1 
The ABC-VEN Matrix 
Category Ⅰ The category consists of drug items belong to AV, AE, AN, BV and CV 
Category Ⅱ The category consists of drug items belong to BE, CE and BN 
Category Ⅲ The category consists of drug items belong to CN 
 
 
2.2.4 Statistical Analysis   
Cumulative cost data of drugs obtained from the McKESSON purchasing detail report 
were checked to ensure completeness and accuracy.  Data were analyzed using the Microsoft 
Excel spreadsheet (Version 16.20, 2018) and Stata, 2017 (Stata Statistical Software: Release 15.  
College Station, TX: StataCorp LLC).  In order to compare the difference in drug cost among the 
aforementioned nine subgroups under ABC-VEN matrix analysis, a parametric statistical test, 
one-way ANOVA, and multiple comparison (post hoc) tests were applied.  The level of 
statistical significance was set at p < 0.05. 
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2.3  Results and Discussion 
2.3.1 ABC Analysis 
After performing the necessary analysis of the drug consumption and expenditure data 
obtained from the acute psychiatric hospital, the drug units were grouped on the basis of ABC 
analysis.  Table 2.2 depicts the result of the ABC analysis which categorizes 27,678 drug units 
consumed by 391 patients between March and July 2018 within the acute psychiatric hospital.  
As per the findings, 585 (2.11%), 5439 (19.65%) and 21654 (78.24%) drug units were found to 
account for $50,168.95 (71.97%), $12,869.05 (18.46%), and $6,673.60 (9.57%), respectively of 
four-month inpatient drug expenditures.  These results are also graphically illustrated in Figure 
2.1  in order to provide a clearer picture of the cumulative percentage of drug units’ amount and 
expenditure.  The cut-offs were not exactly equal to 70%, 20%, and 10%, which is acceptable 
according to the theory of ABC analysis [102, 104, 118, 127, 128].    
 
 Table 2.2   
ABC Analysis 
Note.  Unit cost is not equal to the item cost.  One unit includes any of the following dosage  
forms: Tablet, capsule, patch, bottle, and ampule[129].  Different dosage forms or dosages of the 
same drug can be considered as a different drug.  (For example: ziprasidone 20mg cap, 
ziprasidone 40mg cap, ziprasidone 40mg cap, and ziprasidone 20mg vial are regarded as four 
different drug items). 
 
 
 
 
Category 
Total 
Units 
% of 
Units 
Cumulative  
% Units 
4-Month 
Expenditures  
(Us $) 
% Of  
4-Month 
Expenditures 
Cumulative % 
Expenditure 
A 585 2.11 2.11 50,168.95 71.97 71.97 
B 5439 19.65 21.76 12,869.05 18.46 90.43 
C 21654 78.24 100.00 6,673.60 9.57 100.00 
Total 27678 100.00  69,711.60 100.00  
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Figure 2.1  Cumulative curve of ABC analysis 
 
2.3.2 VEN Analysis 
The results of the VEN analysis are depicted in Table 2.3.  Accordingly, it can be seen 
that 12,604 (45.54%) of drug units in the vital category consumed $28,296.06 (40.59%), 13681 
(49.53%) drug units in the essential category consumed 53.08% ($37,006.29), and 1393 (5.03%) 
in the non-essential category consumed 6.32% ($4,409.25) of the four-month inpatient drug 
expenditures.   
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Table 2.3 
VEN Analysis 
 Note.  In this study, the specified VEN drug list were created in accordance with the World 
Health Organization’s Essential Drug List, 2017 and a clinical pharmacist from the acute 
psychiatric hospital (study samples source).  Different dosage forms and dosages of the same 
drug can be regarded as a single drug (Example: ziprasidone 20mg cap, ziprasidone 40mg cap, 
ziprasidone 40mg cap, and ziprasidone 20mg vial are considered as four drug items).   
 
 
 
2.3.3 ABC-VEN Matrix Analysis 
The results of ABC-VEN matrix analysis are displayed in Table 2.4.  Nine different 
subcategories were further grouped into three main categories: Ⅰ, Ⅱ, and Ⅲ.  There were 12,705 
(45.90%) drug units in category Ⅰ, 13,603 (49.15%) drug units in category Ⅱ, and 1,370 drug 
units in category Ⅲ.  This, in turn, accounted for 86.06% ($59,996.27), 13.43% ($9,361.72), and 
0.51% ($353.61), respectively of four-month inpatient drugs expenditures. 
 
Table 2.4  
ABC-VEN Matrix Analysis  
 
 
Category Total 
units 
% of 
units 
Cumulative% 
units 
4-month 
expenditures  
(US $) 
% of  
4-month 
expenditures 
Cumulative% 
expenditure 
V 12,604 45.54 45.54 28,296.06 40.59 40.59 
E 13,681 49.43 94.97 37,006.29 53.08 93.67 
N 1,393 5.03 100.00 4,409.25 6.32 100.00 
Total 27,678 100.00  69,711.60 100.00  
Matrix Classification Total 
Units 
% Of 
Units 
4-Month Drug 
Expenditures 
(US$) 
 % of 4-Month Drug 
Expenditures  
Category Ⅰ: AV, AE, AN, BV and CV 12,705 45.90 59,996.27 86.06 
Category Ⅱ: BE, CE and BN 13,603 49.15 9,361.72 13.43 
Category Ⅲ: CN 1,370 4.95 353.61 0.51 
Total 27,678 100.00 69,711.60 100.00 
 49 
Thus far, ABC and VEN matrix analyses have been rarely applied to the study of drug formulary 
management  in psychiatric hospitals.  According to literature reviews, other studies, which 
examined similar cases that were not limited to psychiatric hospitals showed a variety of results 
in the drug use and cost percentages of vital, essential, and non-essential items, as well as 
percentage of A, B and C items, as depicted in Table 2.5. 
 
Table 2.5 
Comparison of ABC, VEN, and ABC-VEN Matrix Study Results 
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A 2.11 71.97 5.05 70.08 16.8 70 6.77 70.03 3.45 70.50 
B 19.65 18.46 10.11 19.88 21.8 20.1 19.27 19.98 6.9 19.68 
C 78.24 9.57 84.84 10.04 61.4 9.9 73.59 9.98 89.65 9.83 
V 45.54 40.59 29.12 44.42 35.3 34.3 13.14 19.00 32.41 70.90 
E 49.43 53.08 51.32 47.06 50.4 49.5 56.37 68.00 61.38 28.72 
N 5.03 6.32 19.56 8.52 14.3 16.2 30.49 13.00 6.2 0.38 
Ⅰ 45.90 86.06 32.75 82.55 47.9 82.3 21.00 69.45 33.80 92.33 
Ⅱ 49.15 13.43 49.01 15.66 43.7 16.5 51.17 24.35 60.00 7.29 
Ⅲ 4.95 0.51 18.24 1.79 8.4 1.2 27.83 6.2 6.2 0.38 
Note.  Hospital data used for comparison purposes focused on annual drug use and expenditures 
in hospital pharmacies.  This included both inpatient and outpatient drug prescriptions.  Findings 
of our study were from the four-month actual inpatient drug use and cost in the acute psychiatric 
hospital. 
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According to the ABC analysis, the percentage of category A in our study is similar to the 
findings of  the Neuropsychiatry Hospital [132].  However, a significant difference was found in 
the percentage of drugs in Category B, which showed a similar percentage of drug expenditure.  
Our study also revealed that if we only take VEN analysis into consideration, the vital and/or 
essential drug items can be successfully controlled which accounted for 93.67% of 4-month 
inpatient drug expenditures [119, 130-132].  These diverse results might be attributed to the 
differing hospital types and medical specialties at each facility.  Only one study which applied 
ABC, VEN, and ABC-VEN matrix analysis conducted in a Delhi-based neuropsychiatry hospital 
showed that the vital and essential items accounted for 99.62% (93.79% of drugs) of annual drug 
expenditures of the hospital medical store, while 6.2% (non-essential drugs) accounted for only 
0.38% of annual drug expenditures.  These results included both inpatient and outpatient drug 
costs [132].  
In contrast, the results of our study showed that 5.03% of drugs (non-essential drugs) 
consumed 6.32% of 4-month inpatient drug cost.  Due to the relatively high cost percentage in 
non-essential drugs as compared to the results from similar hospital types, this finding provided a 
partial explanation of keeping drugs listed in the N category under A and B groups for further 
drug monitoring selection. 
 
2.3.4 Drug Monitoring Selection 
In this study, all nine subgroups (Table 2.6) were kept in order to generate the drug list.  
Notably, this drug list needs strict control, with the exception of the subgroup CV, CE, and CN.  
Based on the findings of previous ABC-VEN matrix analyses conducted under the environment 
of general hospitals (non-specialized), the drugs in Category I (AV, AE, AN, BV, and CV as 
shown in Table 2.1) can be seen to be expensive, but important for patients’ treatment.  Due to 
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these factors, Category I drugs require strict and careful monitoring [17][133].  Therefore, after 
conducting ABC-VEN matrix analysis, the following subcategories within Category I drugs were 
selected for composing the drug list that required strict drug cost control: AV, AE, AN, BV.  
Category II drugs (BE, CE, and BN; refer to Table 2.1) are deemed less important, considering 
the expenditure and patient treatment.  In our study, subgroups BE and BN were kept for the 
further regression study, but the subgroup CE was excluded.  Although the subgroup BN 
contains drugs of less importance in terms of patient treatment, it does contain drugs of moderate 
importance for expenditure.  Since the guiding concept of the entire study is intended to help 
acute psychiatric hospitals save money on inpatient drug costs, we kept the subgroup BN in the 
drug list that needs strict control.  In addition, 5.03% of drugs consumed 6.32% of the four-
month drug cost under N category, which is sufficient enough to attract attention in order to 
determine specific drugs under this category that contribute to the uncommon results, especially 
when compared to a similar study conducted in a neuropsychiatric hospital (in N category, 6.2% 
of drugs consumed 0.38% of the annual drug cost).  Large differences were found between drug 
cost percentages (see Table 2.6).   
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Table 2.6  
ABC-VEN Nine Subgroups  
Subgroups Total 
Units 
% of 
Units 
4-Month Drug 
Expenditures 
(US$) 
 % of 4-Month 
Drug 
Expenditures  
Average Cost per 
Unit (US$) 
AV 484 1.75 18,468.74 26.49 385.16 
AE 99 0.36 28,744.17 41.23 290.35 
AN 2 0.01 2,956.04 4.24 1478.02 
BV 2,921 10.55 6,404.66 9.19 2.19 
BE 2,497 9.02 5,364.79 7.70 2.15 
BN 21 0.08 1,099.60 1.58 52.36 
CV 9,199 33.24 3,422.66 4.91 0.37 
CE 11,085 40.05 2,897.33 4.16 0.26 
CN 1,370 4.95 353.61 0.51 0.26 
Total 27678 100.00 69,711.60 100.00 2.52 
 
 
The reason for not selecting subgroup CV from Category I and CE from Category Ⅱ, as 
the drugs that need strict control, are supported by the data.  Table 2.6 depicts that CV (33.24% 
of total drug units over a four-month period) and CE (40.05% of the total units over the four-
month period) were only accountable for 4.91% and 4.16% of the total 4-month drug cost, 
respectively.  Even if the usage percentage of drugs in CV (33.24%) and CE (40.05%) were 
found to be among the top two in all subgroups, the low drug cost (73.29% of the total drug units 
consumed 9.07% of 4 months drug cost) was not a compelling enough reason to include these 
drugs for further analysis.  Therefore, it can be inferred that even a large number of drugs used 
under the subgroups CV and CE will not have a significant impact on  inpatient drug costs.  In 
contrast, a large number of drugs used under in other subgroups in Category I (AV, AE, AN, and 
BV) and Category Ⅱ (BE and BN) will impose a major financial burden on the hospital.   
 53 
One-way ANOVA was performed to explore the cost differences among these nine 
subgroups.  However, subgroups AN (one drug item) and BN (two drug items) could not be 
included due to the small sample size within each subgroup.  In order to further support the 
reason behind not selecting subgroups CV and CE, post hoc tests (Bonferroni) were used to 
determine the differences between AV, AE, CV, and CE.  According to the results,  a statistically 
significant difference was found in the inpatient drug cost between the “AV-CV” group 
(p<0.05), the “AV-CE” groups (p<0.05), the “AE-CV” group (p<0.05), as well as the “AE-CE” 
group (p<0.05).  However, no difference was found between the “CV-CE” group (p=1.000).  
Therefore, it can be concluded that both groups can be excluded.   
The CN subgroup was excluded because it is the only subgroup under Category Ⅲ that 
included drugs of low importance, both in terms of drug cost and patient treatment.  Hence, we 
retained drugs under category AV, AE, AN, and BV, BE, and BN based on the specific study 
concept and hospital type.  The 51 drugs from subgroup AV, AE, AN, and BV, BE, and BN  
were selected in order to enter the medications under control (MUC) list, as shown in Table 2.7. 
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Table 2.7  
Medications Under Control (MUC) List 
 VEN Drug Information  Unit Unit Cost 
(US$) 
Cost 
(US$) 
ABC 
1 V aripiprazole 400mg/2ml susp 5 1935.21 9676.05 A 
2 V aripiprazole 5mg tab 353 8.13 2869.89 A 
3 V fluticasone 110mcg inh 9 205.57 1850.13 A 
4 V lurasidone 20mg tab 46 34.10 1568.60 A 
5 V fluticasone-vilanterol 100-25mcg inh 14 101.79 1425.06 A 
6 V olanzapine 10mg tab  57 18.93 1079.01 A 
 Total   484   18468.74   
 
      
7 E insulin lispro 100 units/1ml 3ml syr 32 490.61 15699.52 A 
8 E insulin glargine 100units/ml 100units/1ml 
3ml syr 
28 320.12 8963.36 A 
9 E tuberculin, purified protein derivative 35 67.67 2368.45 A 
10 E risperidone 25mg syr 4 428.21 1712.84 A 
 Total   99   28744.17   
 
      
11 N paliperidone 156mg 1.5ml syr 2 1478.02 2956.04 A 
 Total   2   2956.04   
 
      
12 V lurasidone 40mg tab 16 33.49 535.84 B 
13 V apixaban 5mg tab 83 5.80 481.40 B 
14 V umeclidinium 62.5mcg inh 10 47.93 479.30 B 
15 V albuterol 90mcg inh 25 18.94 473.50 B 
16 V lurasidone 80mg tab 14 33.49 468.86 B 
17 V quetiapine XR 50mg tab 56 7.49 419.44 B 
18 V quetiapine 100mg tab 1461 0.25 365.25 B 
19 V fluticasone 220mcg inh 1 317.02 317.02 B 
20 V quetiapine XR 200mg tab 23 13.36 307.28 B 
21 V desvenlafaxine 50mg tab 29 10.51 304.79 B 
22 V divalproex ER (24hr) 500mg tab 141 2.16 304.56 B 
23 V duloxetine 30mg cap 157 1.56 244.92 B 
24 V rivaroxaban 20mg tab 23 9.48 218.04 B 
25 V pregabalin 75mg cap 31 7.02 217.62 B 
26 V asenapine 5mg tab 12 17.30 207.60 B 
27 V linagliptin 5mg tab 19 10.64 202.16 B 
28 V sitagliptin 25mg tab 16 12.57 201.12 B 
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(Table 2.7 Continued) 
29 V ziprasidone 20mg vial 45 4.18 188.10 B 
30 V divalproex ER (24hr) 250mg tab 112 1.46 163.52 B 
31 V benztropine mesylate 1mg tab 626 0.25 156.50 B 
32 V pregabalin 50mg cap 21 7.04 147.84 B 
 Total   2921   6404.66   
 
      
33 E chlorpromazine 50mg tab 116 8.16 946.56 B 
34 E neomycin/polymyxin b/hydrocort 14 66.76 934.64 B 
35 E nicotine transdermal 21 mg patch 449 1.41 633.09 B 
36 E mag/alum hydrox simethicone 30ml liq 227 1.90 431.30 B 
37 E oxycodone ER 20mg tab 59 6.33 373.47 B 
38 E haloperidol decanoate 100mg/1ml 1ml  6 37.51 225.06 B 
39 E ketoconazole 2% topical cream  11 20.32 223.52 B 
40 E nicotine transdermal 14 mg patch 141 1.53 215.73 B 
41 E risperidone 2mg tab 601 0.31 186.31 B 
42 E bimatoprost 0.01% ophthalmic solution 1 163.31 163.31 B 
43 E chlorpromazine 25mg/1ml 2ml  6 26.71 160.26 B 
44 E clozapine 100mg tab 168 0.94 157.92 B 
45 E lorazepam 2mg/1ml 1ml  96 1.53 146.88 B 
46 E risperidone 1mg tab 544 0.27 146.88 B 
47 E fluphenazine 2.5mg tab 54 2.64 142.56 B 
48 E gatifloxacin zymaxid 0.5% ophthalmic 
solution  
3 46.31 138.93 B 
49 E insulin NPH 30 unit 0.3ml 1 138.37 138.37 B 
 Total   2497   5364.79   
 
      
50 N dalfampridine ER 10mg tab 20 36.02 720.40 B 
51 N  rifaximin 550mg tab  1 379.20 379.20 B 
 Total  21  1099.60   
Note.  The tuberculin skin test involves monitoring the immune reaction to an injection of 
Purified Protein Derivative (PPD) insulin NPH 30 unit 0.3ml [134].  NPH stands for neutral 
protamine Hagedorn.  NPH insulin starts lowering blood glucose within 1 to 2 hours after 
injection.  Its strongest effect is felt 6 to 10 hours after injection but keeps working about 10 
hours after injection.  It is also referred to as N insulin. 
Abbreviation: cap, capsule; tab, tablet; susp, suspension; inh, inhaler; syr, syringe; liq, liquid;  
 
 
In the present study, 51 drug items (14.01% of the 364 total drug items) consumed 
90.43% of the four-month drug cost.  ABC-VED matrix analysis allowed the application of 
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stringent managerial control measures to all the 51 drug items under the following categories: 
AV, AE, AN, and BV, BE, and BN, all of which are expensive and vital/essential, or expensive 
and non-essential subgroups.  Traditionally, drugs in the Category Ⅰ (AV, AE, AN, BV, and CV) 
among ABC-VEN matrix studies are always kept for cost control.  However, CV was excluded 
from further study due to its low-cost percentage (on the basis of high use percentage).  This 
study is unique in that subgroups BE and BN were kept under Category II (BE, BN, and CN) for 
future analysis.  Additionally, CN was also excluded from the study due to its low cost 
percentage.  Meanwhile BN was retained. due to its extremely low percentage of drug use and 
relatively high average cost per unit ($52.36 - see Table 2.6).  As compared to the average cost 
per unit of CV ($0.37), CE ($0.26), and CN ($0.26), we have a more compelling reason to retain 
BN.  If the same proportion of drug use is increased in BN, CV, and CE, the drug cost growth of 
the subgroup BN will be much larger than that of the subgroups CV and CE owing to its higher 
average unit cost.  The importance of the MUC list lies in the fact that the secondary diagnosis 
groups (DRGs) will be generated by the assistance of 51 medications. 
 
2.4 Limitation 
The empirical results reported herein should be considered in light of some limitations, 
which could be addressed in future research.  First, this study  focused only on four-month drug 
expenditure data while other similar studies usually collect data of annual drug costs.  Second, 
this study did not utilize the annual drug storage data to generate ABC, VEN, and ABC-VEN 
analysis results.  Instead, it used actual inpatient drug consumption data to perform the same 
analysis.  The resulting comparison is depicted in Table 2.5.  The difference between our study 
and the one conducted in another neuropsychiatric hospital might be attributed to the different 
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time span of data (4 months vs. 12 months) different data resources (actual inpatient drug usage 
and cost data vs.  annual drug storage data), or different hospital and patient types (inpatient drug 
costs in the acute psychiatric hospital vs. inpatient and outpatient drug cost in either psychiatric 
hospitals or general hospitals).   
 
2.5  Conclusion 
The application of scientific inventory management tools is necessary for optimizing the 
management of pharmacy budgets in acute psychiatric hospitals.  It is imperative that the 
purchasing and supervision of drug items be done based on the importance in terms of treatment 
and cost.  ABC-VEN matrix analysis can be applied in psychiatric hospitals to select the drugs 
that require strict management control for efficient utilization of hospital funds and resources 
Based on the results of this study, stringent drug cost control applied to acute psychiatric 
hospital drugs under subgroups AV, AE, AN, and BV, BE, and BN may be beneficial.  It is 
important to note that drugs under AV, AE, BV, and BE are either vital or essential, and are 
generally kept in the inventory.  In light of the high cost of drugs under AV, AE, and AN, strict 
control should be exercised on the prescription and utilization patterns of these medications.  In 
addition, dedicated efforts are needed for medications under subgroup AN, BN, which make up a 
significant part of the pharmacy budget in the acute psychiatric hospital, such as looking for 
better pricing structure, identifying therapeutic alternatives, and allowing patients to bring their 
home medications for use during the admission.  However, it must also be considered that such 
attempts must not compromise the quality of health care services.  Drugs under subgroups CV 
and CE should receive lower or moderate controls considering their low percentage on inpatient 
drug cost. 
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This study applied the concept of pharmacy formulary management tool, ABC analysis, 
VEN analysis, as well as ABC-VEN matrix analysis to select 51 drugs requiring strict control on 
the basis of cost and clinical criticality.  In addition, this study can be deemed as a fundamental 
research that details underlying factors for the regression analysis on high drug cost, which is 
discussed in Chapter 3.  
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CHAPTER 3: LEADING DRIVERS STUDY 
 
3.1  Introduction and Motivation 
With an increased emphasis on value-based care, healthcare organizations are 
increasingly striving to provide consistent, high quality, and safe medical services, while 
appropriately reducing costs in healthcare.  However, the United States spent approximately 18% 
of its gross domestic product on health care, and the cost of hospital care amounted to 33% of the 
overall cost in 2017 [135].  With reduced reimbursements for hospital inpatient care  by private 
health insurance, Medicare, and Medicaid [136], unnecessary practices must be identified and 
minimized [137, 138].  
Under the current U.S. healthcare model, Medicare payments are made based on a 
predetermined, fixed amount.  This means, hospitals are reimbursed using a Prospective Payment 
System (PPS).  The cost of a particular service is derived from service-related classification 
systems, such as diagnosis-related groups (DRGs) for inpatient hospital services [58].  In 
particular, the Center for Medicare and Medicaid Services (CMS) uses separate PPSs for 
reimbursement in acute inpatient hospitals, such as Inpatient Psychiatric Facility PPS (IPF PPS) 
[139].  Meanwhile the IPF PPS provides patient-level reimbursement adjustments on the basis of 
patient age, medical severity diagnosis-related groups (MS-DRGs), and selected comorbidity 
categories. Every hospital has a unique payment rate per individual.  This rate can also be 
referred to as the “base payment rate”.  Each DRG is assigned a relative weight (RW) according  
to the average recourses consumed by each hospital to care for the patient assigned to each DRG.  
In order to be profitable under this model, hospitals need to provide treatment for illnesses that 
requires less spending than the DRG-based reimbursement they receive.  Otherwise, hospitals are 
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held responsible for any costs that exceed the reimbursement amount.  Therefore, hospitals are 
developing processes to help the scenarios where cost exceeds reimbursement.  Under such a 
circumstance,  the current study was aimed to help assess this issue from the perspective of 
medication costs in an inpatient setting of acute psychiatric hospitals.  
Inpatient mental health treatment is aimed at helping people who require stabilizing 
mental and behavioral symptoms.  Many patients with mental disorders, including but not 
limited to schizophrenia, bipolar disorder, major depression, schizoaffective disorder, and post-
traumatic stress disorder (PTSD) experience flare ups.  When serious mental illness occurs (also 
known as acute mental illness), inpatient hospitalization may be needed [140].  While medication 
usage and cost pattern data in acute psychiatric hospital settings have rarely been reported, a 
large number of studies on inpatient medication costs in other settings have been undertaken in 
the past decade [4, 21, 141-144].   
In an inpatient setting, pharmacy expenditures comprise approximately 20% of the total 
operating budget and are commonly considered as the top area to prioritize potential savings 
[145].  Unlike other countries, the United States does not regulate medication prices; pharmacy 
benefit managers (PMBs) use their negotiating power to secure better price and discounts from 
pharmaceutical companies. However, it does not necessarily lower the price for patients or the 
inpatient pharmacy. This may be the result of the complicated market structures combined with 
the decreasing competition among PMBs [146]. For instance, the number of PBMs reduced from 
60 to 30 from 2003 to 2016 [147, 148].  Even though many findings suggest the desire for a 
more concerted effort to reduce medication prices and administrative costs, policy constraints 
only provide short-term curtailment  [135].  Our study proposed that ascertaining the leading 
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drivers of increasing inpatient medication cost in psychiatric hospitals can be a pivotal 
component of cost control management in psychiatric hospital pharmacies.   
In the Chapter 2, the medication cost management study demonstrated how medication 
cost management can be applied in acute psychiatric hospital settings.  Following a systematic 
ABC-VEN matrix analysis, 51 medication items, also known as medications under control 
(MUC) were selected and added to a list of medications that need strict control. 
This study informed the search for effective cost management strategies and predictions 
for medication budget within the acute psychiatric hospital setting in a novel manner.  The goal 
of this study was to identify a relationship between potential factors including patient 
demographics, diagnosis , length of stay (LOS), MUC, insurance type and increasing inpatient 
medication costs (dependent variable) in an acute psychiatric hospital.  The potential factor, 
diagnosis, which contains principal diagnosis (ICD-10-CM codes) and secondary diagnosis 
(secondary major diagnostic categories, SMDC) were included in the regression model.  A 
regression model was used to identify the relationship between diagnosis categories and cost 
while controlling for other factors.   
The factors used in the cost regression model are displayed below.  In addition, LOS can 
be considered as a proxy for hospital medication cost per patient through the application of 
“count outcome” regression modeling, a method that has been rarely used in psychiatric hospital 
pharmacy setting.   
 
Cost regression model: 
                       Cost = f (patient demographics, diagnosis category, LOS, MUC,  
                                       insurance type, and month admitted) 
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3.2  Literature Justification of Selecting Factors in Regression Model 
3.2.1 The Demographic Factor-Age/Gender-MBD 
National Institute of Mental Health (NIMH) data showed that out of 44.7 million adults 
with any mental illness (AMI), 19.2 million (43.1%) received mental health treatment.  The 
National Survey on Drug Use and Health (NSDUH) defines mental health treatment as having 
received inpatient treatment/counseling or outpatient treatment/counseling, or having used 
prescription medications for problems with emotions, nerves, or mental health.  Older adults are 
not in a better mental health than younger adults [149]. The percentage of adults with AMI aged 
50 and older (71.5%) is among the highest age group as compared to 18-25 years young adults 
(51.5%) and 26-49 years adults (66.1%) [150].  The definition of AMI excluded patients with a 
developemtal or substance use disorder.  Notably, 67% of adults with major depression received 
mental health treatment.  Among these, 80.9% are 50 years of age and older.  This is followed by 
individuals who are 26-49 years of age (67.4%) and 18-25 years of age (46.8%).  With the 
increasing age, the elderly continue to accept the challenges associated with additional health 
problems beyond their mental health.  It is important to note that untreated mental health 
problems are linked to poor physical health outcomes.  This includes an increase in disability and 
chronic disease, as well as lower quality of life.  The elderly may be prone to anxiety, 
depression,  or using alcohol or medications to manage their mood [151]. In addition, gender 
differences have been reported [152].  In the United States, mental illness was more prevalent 
among women (21.2 %) in comparison to men (14.3 %).  Women were also 50-70% more likely 
to be diagnosed with major depression (43.2 vs.  27.2 %, p < 0.001) or anxiety disorders (41.8 
vs.  24.4 %, p < 0.001) [153].  In this study, we examined whether age and gender differences in 
mental patients have an impact on their inpatient medication costs. 
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3.2.2 Mental Illnesses - Other Chronic Illnesses 
3.2.2.1 Depression.  According to the World Health Survey (WHS), as compared to 
patients only diagnosed with either depression or chronic disease, a comorbid diagnosis 
involving depression and chronic disease affects patient health incrementally [154]. This study 
enables one to observe whether patients with comorbidities generate higher inpatient medication 
costs in acute psychiatric hospitals. 
People with chronic diseases, specially chronic conditions that are not a mental-health 
diagnosis, are known to have a higher risk of depression [39, 155].  A common explanation for 
this is that the chronic conditions trigger anxiety and stress that can also  
generate symptoms of depression [156].  Common chronic illnesses among people with 
depression include cancer, coronary heart disease, diabetes, rheumatoid arthritis, epilepsy, 
multiple sclerosis, stroke, Alzheimer’s disease, human immunodeficiency virus, acquired 
immunodeficiency syndrome (HIV/AIDS), Parkinson’s disease, and Systemic lupus 
erythematosus, and others.  Studies have demonstrated that people with depression and other 
diseases tend to exhibit more severe symptoms of both diseases.  Historically, individuals with 
both a chronic medical condition and depression have faced higher medical expenses than those 
that did not suffer from depression [157].   
Beyond patients with other chronic diseases being more likely to suffer from depression, 
people with depression had a higher likelihood of developing other chronic diseases.  The 
primary reason behind this is that many patients with depression may not seek medical services.  
In addition, they may experience more difficulties addressing their health, such as seeking 
appropriate medical care and adhering to prescription medications [158].  As an example of the 
challenges for adherence, antidepressants are commonly used to treat depression and usually take 
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two to four weeks to work, which can negatively impact adherence.  Several different 
antidepressant medications may need to be prescribed before finding one that improves the 
symptoms and has manageable side effects [159][146]. In this scenario, the cost of medications 
for depression treatment are increased.  
3.2.2.2 Other mental illnesses.  Inpatient medication cost for patients with schizophrenia 
has historically been expensive. Schizophrenia is not as common as other mental illnesses, but 
the symptoms of this ailment can be very disabling.  Interactions between genes and aspects of 
an individual’s growth environment contribute to the development of schizophrenia, but there is 
no evidence to suggest that chronic disease can trigger the symptoms of schizophrenia [160].  
Since the causes of schizophrenia are still being investigated, treatments mainly focus on 
eliminating the symptoms [161].  Antipsychotic medications are usually taken orally, and some 
antipsychotics are injected once or twice per month, or in some instances every 6 to 8 weeks.  
For example, risperidone injection 25mg is generally given once every two weeks.  Patients may 
also need to take risperidone by mouth in tablet or liquid form during the first three weeks of  
injections.  The cost of risperidone injection 25mg is $428.21 per injection or nearly one 
thousand dollars per month, which excludes the cost of oral antipsychotic medications used by 
patients during this treatment period.  Expensive medications such as the long-acting injectable 
antipsychotics may not make up a high percentage of medications used, but the cost of them can 
be very significant. 
Unlike Schizophrenia , bipolar disorder, also known as manic-depressive illness, is one of 
the most common mental illnesses.  This disorder causes unusual changes in mood, energy, and 
activity level.  People with bipolar disorder are also at higher risk for migraine headaches, 
thyroid disease, heart disease, diabetes, obesity, and several other chronic conditions.  As is the 
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case with depression, patients often need to try several different medications before finding the 
ones that work best to help alleviate symptoms.  Mood stabilizers, atypical antipsychotics, and 
antidepressants are generally given to treat bipolar disorder [162].   
 
3.2.3 Comorbidity 
Diagnosis of a physical disease has been found to have a profound impact on the mental 
health of an individual.  The impact of chronic disease on mental health also leads to increased 
substance abuse rates [163].  Meanwhile, excessive alcohol use can also increase the risk of 
developing diabetes, particularly for women [164, 165].  The life-threatening disease cirrhosis 
can be caused by any substance abuse, which is particularly prevalent with abuse of alcohol, 
steroids, inhalant, and heroin [166].  When a patient is suffering from heart disease, the use of 
medications can affect the heart rate and exacerbate symptoms, resulting in a higher chance of 
having a heart attack or stroke [167-169].  Chronic obstructive pulmonary disease (COPD), 
chronic bronchitis, asthma, and emphysema are lung diseases that can be triggered or otherwise 
affected by substance abuse [170].  Patients with chronic diseases have a high rate of mental 
health issues, which has been demonstrated in a large review from the Substance Abuse and 
Mental Health Services Administration (SAMHSA) [171].  
 
3.2.4 Major Diagnostic Categories (MDC)/Diagnosis Related Groups (DRGs) 
MDC are formed by dividing all possible principal diagnoses from ICD-10-CM (ICD, 
International Classification of Diseases; CM, Coordination and Maintenance Committee) into 25 
mutually-exclusive diagnosis areas [172].  The DRG codes are also mapped or grouped into 
MDC codes.   MDC 1 to MDC 23 are grouped in accordance with the principal diagnoses.  MDC 
19 is assigned to Mental Diseases and Disorders.  DRG codes 876 to 887 are grouped into MDC 
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19.  In this study, hospital pharmacies can explore which specific DRGs have the  highest impact 
on medication cost by analyzing the relationship between the medication cost and DRGs.   
 
3.2.5 Primary Diagnosis and Principal Diagnosis 
In an inpatient setting, the primary diagnosis is related to the most serious and/or 
resource-intensive condition.  Both the primary and principal diagnoses are typically the same, 
but that is not always the case.  According to the ICD-10-CM official guidelines for Coding and 
Reporting, principal diagnosis refers to the condition which causes admission into the hospital.  
Principal diagnosis denotes what resulted in the reason, and not necessarily the condition that 
brought the patient into the emergency room [173].  The inpatient report used for data collection 
in this study only contains the information of principal diagnosis (principal ICD-10-CM codes)  
 
3.2.6 Secondary Diagnosis 
Secondary diagnoses are comprised of conditions that coexist at the time of admission, 
develop subsequently, or affect the patient care during the current episode.  This condition needs 
to involve one of the listed medical services in order to constitute a secondary diagnosis: clinical 
evaluation, therapeutic treatment, diagnosis studies, an extended LOS, or increased nursing care 
[174].  In this study, any secondary codes that yielded medication treatment were identified as a 
secondary diagnosis.   
 
3.2.7 Medications Under Control (MUC) 
 
MUC is one of the leading factors of higher medication cost and longer LOS shown by  
results of the ABC, VEN, and ABC-VEN matrix analysis in study 1.  MUC comprises 51 
medications (including 21.77% of total medication units) that accounted for nearly 91.43% of 
four-month inpatient medication costs.   
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3.2.8 Determinants of Length of Stay (LOS) for Patient with Mental Illness 
LOS has been a key indicator of hospital efficiency and quality of care [175].  However, 
longer stays result in higher treatment costs and extra cost burdens to hospitals.  From the 
perspective of clinical and hospital financial management, LOS has become one of the most 
watched indicators in all hospitals and medical systems [176-179]. Substantial studies conducted 
in general medical hospitals have focused on how LOS is affected by hospital for-profit status, 
hospitalists, physicians and nursing involvement, hospital volumes, and patient insurance status 
[180-184].   
According to a review of regression analyses to determine the contributing factors of the 
determinants to LOS for adults in the United States, female gender, larger hospital sizes, and 
psychosis (ICD-10-CM code: F20–29), were associated with a longer LOS [185].  Another study 
conducted in the United Kingdom pointed out that a diagnosis of psychosis (ICD-10-CM code: 
F20–29) and male gender identity was associated with a longer LOS as compared to the 
reference groups [186].  
Factors that are tentatively associated with LOS have been studied in a university-
affiliated, not-for-profit psychiatric hospital.  Diagnoses including schizophrenia, schizoaffective 
disorder, bipolar disorder, major depressive disorder, other psychoses, and other affective 
disorders are important predictors of LOS.  The number of psychiatric conditions was also linked 
to longer stays.  Comorbidity was weakly associated with longer stays [187]. In our study, 
principal and secondary diagnosis information was included in the form of ICD-10-CM codes 
and secondary major diagnosis categories (MDC) in the count regression model in order to 
evaluate the association with LOS.  In addition, comorbidity was also tested in order to explore 
its association with LOS.    
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3.2.9 Insurance 
Many studies have revealed a strong association between insurance type and LOS [188-
190].  Patients with Medicaid or Medicare were hospitalized an average of 14 days, while those 
with private insurance had a median LOS of 10 days [187].  However, uninsured have rarely 
been compared with Medicare, Medicaid and private insurance.  According to one study 
conducted in a community hospital concerning the psychiatric stays, publicly paid 
hospitalizations (Medicare and Medicaid) were found to be significantly longer than those 
covered by private or uninsured payers among five diagnoses: (1) schizophrenia; (2) bipolar 
disorder; (3) depression; (4) drug use disorder; and (5) alcohol use disorder [57].   
 
3.2.10 Month Admitted 
Mental and behavioral disorders have been considered to have seasonal variation.  
According to a six-year study, there were statistically significant peaks of admission in the spring 
and fall among patients with mental disorders.  Moreover, alcoholism-related admission also 
showed an increase in spring [191].  Exploration of the admitted month may help ascertain the 
seasonal variation in an acute psychiatric hospital.  Similar to variable insurance, month admitted 
was also added as controls in order to better isolate the relationship between clinical variables 
(ICD-10-CM codes, SMDC, MUC) and LOS.   
 
3.3  Data and Empirical Methods 
400 consecutive, adult patients admitted with a mental health condition as their primary 
diagnosis that were then hospitalized in a 35-bed, licensed, not-for-profit acute psychiatric 
hospital between March 16th and July 27th were enrolled in this study.  Patients’ data were 
collected from the patient report entitled Coding and Summary in the electronic record.  
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Descriptive statistics can be found in Table 3.1.  There were fewer patients in the age group 76 
years old and over than other age groups. However, there was no statistically significant 
differences between medication costs among different age groups.  There were slightly more 
male patients (51.73%) than female patients (48.27%), but not a statistically significant 
difference in their medication cost.  In addition, no significant difference existed in cost among 
different insurance groups.  Medicare beneficiaries represented 60% of the sample but only 
18.21% of the sample is over 65 years of age (66-75, 15.03%; 76 and over, 3.18%).  This 
suggests a large fraction that qualifies for Medicare based on disability rather than age. In 
addition, Medicaid beneficiaries could not be identified in the sample due to the unavailability of 
specific insurance information shown in the report of Coding and Summary. For length of stay. 
we found that 78.32% of patient stayed in the hospital less than seven days.   
During the data collection period, six patients did not take any medication during the 
hospitalization, and data of three patients were not available due to a software issue (MUC list 
was generated from 391 patients in Chapter 2, see Table 2.1).  Because a primary goal of this 
analysis was to determine if SMDC was associated with higher inpatient medication costs, 45 
patients without a secondary diagnosis were excluded from the analysis.  Therefore, regression 
results reported below are based on a sample of 346 patients. 
Patients’ private information, including demographic and clinical data involved in this 
study were all de-identified and no intervention was given to the patients for any research 
purpose, therefore this study was exempt from Institutional Review Board (IRB) review of the 
University of the Pacific.  Data collected from the patient report of Coding and Summary 
included the following: age, gender, principal and secondary diagnosis code (ICD-10-CM code), 
comorbidity, LOS, patient admission and discharge date, and insurance type.   
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Using SMDC as a potential factor allowed observation of which specific Secondary 
major diagnoses contributed to higher inpatient medication costs.  Adding comorbidity status 
helped to identify which type of comorbidity resulted in a higher inpatient medication cost.  In 
this study, comorbidity status was determined using the principal diagnosis code and secondary 
diagnosis code.  The category of comorbidity was developed based on the structure of “principal 
diagnosis + secondary diagnosis”.  Six subgroups were listed: (1) no comorbidity; (2) Psych 
(psycho diagnosis) + Med (medical diagnosis); (3) Psych (psycho diagnosis) + Psych (psycho 
diagnosis); (4) Psych (psycho diagnosis) + SUD (substance use disorder diagnosis); (5) SUD 
(substance use disorder diagnosis) + Med (medical diagnosis); and (6) SUD (substance use 
disorder diagnosis) + SUD (substance use disorder diagnosis).  Table 3.1 showed that the portion 
of Psycho + Med is much more than the portion of other comorbidity groups.  Comorbidity, as a 
potential factor,  may enable one to see if the six combinations of diagnosis structure yield the 
statistically different results for inpatient medication costs. Thus, comorbidity was used to 
examine the extent of impact on inpatient medication costs. 
    MUC, as defined and discussed in Chapter 2, is hypothesized to be a significant factor 
as discussed in Chapter 2.  Accordingly, MUC contains 51 medications (including 21.77% of 
total medication units) that accounted for nearly 91.43% of four months of inpatient medication 
costs.  These 51 medications were a significant factor in the finalization of the secondary ICD-
10-CM code for each patient. 
 The descriptive statistics in Table 3.1 showed patients who took medications under MUC 
had a statistically significant higher cost than patients that did not.  
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Table 3.1  
Descriptive Statistics for Admissions.  (n=346) 
Variable 
 
No. of 
Patient 
Proportion 
(%) 
Cost (US$ 65,169.76) 
Total (US$) Mean 
(US$) 
Std.  Dev p 
value* 
Age (n=346)         0.108 
    18-25 47 13.58 5203.78 110.718 268.601  
    26-35 49 14.16 12239.70 249.790 604.603  
    36-45 63 18.21 8304.73 131.821 242.688  
    46-55 48 13.87 5820.09 121.252 218.377  
    56-65 76 21.97 22350.12 294.081 510.512  
    66-75 52 15.03 9677.44 186.105 445.287  
    76 and over 11 3.18 1573.00 143.082 172.742  
       
Gender (n=346)      0.301 
    Female 167 48.27 27489.47 164.608 357.625  
    Male 179 51.73 37680.29 210.504 456.296  
       
Insurance type 
(n=346) 
     0.808 
    Private 
(including 
Medicaid) 
136 39.31 22590.72 166.108 425.159  
    Medicare 206 59.54 42023.75 203.999 406.126  
    Uninsured 2 0.58 81.66 40.83 3.394  
    Dual eligible 
(Medicare and Medicaid) 
2 0.58 473.63 236.815 303.766  
       
MUC (n=346)      <0.05 
    Present 261 75.43 64133.80 245.723 4459.641  
    Absent 85 24.57 1035.96 12.188 23.456  
       
Comorbidity (n=346)       0.051 
    No comorbidity 11 3.18 572.10 52.009 133.956  
    Psych + Med 234 67.63 55074.88 235.363 461.612  
    Psych + Psych 36 10.40 3593.39 99.816 351.482  
    Psych + SUD 36 10.40 1413.38 39.261 54.526  
    SUD + Med 28 8.09 4514.31 161.225 295.495  
    SUD + SUD 1 0.29 1.70 1.7 N/A  
           
Length of stay 
(LOS) (n=346) 
     <0.05 
   One weeks 271 78.32 37590.16 138.709 328.971  
   Two weeks 49 14.16 13874.44 283.152 514.610  
   Three weeks 15 4.34 4892.60 326.173 470.390  
   Three weeks + 11 3.18 8812.56 801.142 889.959  
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Month Admitted 
(n=346) 
     0.226 
    March  1 0.29 554.89 554.890 N/A  
    April 16 4.62 5365.80 335.363 588.134  
    May 128 36.99 28461.24 222.353 459.715  
    June 122 35.26 16699.77 136.883 294.280  
    July 79 22.83 14088.06 178.330 438.631  
       
Principal diagnosis 
(ICD-10-CM code) 
(n=346) 
     0.365 
    F03.  
Unspecified 
dementia 
1 0.29 2.43 2.430 N/A  
    F10.  Alcohol 
related disorders 
26 7.51 3594.85 138.264 273.992  
    F11.  Opioid 
related disorders 
6 1.73 498.34 83.057 108.907  
    F12.  Cannabis related 
disorders 
2 0.58 501.17 250.585 238.005  
    F15.  Other 
stimulant related 
disorders 
2 0.58 17.59 8.795 10.034  
    F19.  Other 
psychoactive substance 
related disorders 
2 0.58 838.65 419.325 588.263  
    F20.  Schizophrenia 55 15.90 9559.46 173.808 357.286  
    F22.  Persistent 
delusional disorder 
1 0.29 1.86 1.860 N/A  
    F23.  Acute and 
transient psychotic 
disorder 
1 0.29 32.03 32.030 N/A  
    F25.  Schizoaffective 
disorders 
42 12.14 16803.87 400.092 692.676  
    F29.  Unspecified 
nonorganic psychosis 
19 5.49 3092.79 162.778 369.583  
    F31.  Bipolar affective 
disorder 
78 22.54 11013.49 141.199 283.559  
    F32.  Major depression 
disorder, single episode 
10 2.89 3276.31 327.631 616.138  
    F33.  Major depression 
disorder, recurrent 
96 27.75 15495.73 161.414 391.537  
    F39.  Unspecified 
mood [affective] disorder  
1 0.29 2.85 2.850 N/A  
    F41.  Other anxiety 
disorders 
3 0.87 14.91 4.970 2.957  
    F60.  Specific 
personality disorders 
1 0.29 423.43 423.430 N/A  
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Secondary major 
diagnostic Categories 
(n=346) 
                                                                                                            <0.05 
                    
                                        
    1.  Nervous System 
(020-103) 
18 5.20 3092.69 171.816 417.240  
    2.  Eye (113-125) 1 0.29 1780.22 1780.220 N/A  
    4.  Respiratory System 
(163-208) 
33 9.54 6328.40 191.770 198.608  
    5.  Circulatory System 
(215-316) 
42 12.14 4834.91 115.117 255.749  
    6.  Digestive System 
(326-395) 
9 2.60 2441.37 271.263 631.715  
    7.  Hepatobiliary 
System and Pancreas 
(405-446) 
2 0.58 391.35 195.675 262.513  
    8.  Musculoskeletal 
System and Connective 
Tissue (453-566) 
14 4.05 2420.30 172.879 513.639  
    9.  Skin, Subcutaneous 
Tissue and Breast (573-
607) 
2 0.58 57.18 28.590 4.865  
  10.  Endocrine, 
Nutritional and 
Metabolic System (614-
645) 
53 15.32 21616.65 407.861 614.248  
  11.  Kidney and Urinary 
Tract (652-700) 
14 4.05 5068.67 362.048 581.201  
  12.  Male Reproductive 
System (707-730) 
1 0.29 0.56 0.560 N/A  
  13.  Female 
Reproductive System 
(734-761) 
1 0.29 1.96 1.960 N/A  
  19.  Mental Diseases 
and Disorders (876-887) 
56 16.18 4660.86 83.230 289.120  
  20.  Alcohol/Drug Use 
or Induced Mental 
Disorders (984-897) 
31 8.96 1065.11 34.358 41.441  
  21.  Injuries, Poison and 
Toxic Effect of Drugs 
(901-923) 
 
1 0.29 38.07 38.070 N/A  
  23.  Factors Influencing 
Health Status and Other 
Contacts with Health 
Services (939-951) 
68 19.65 11371.46 167.227 364.152  
Note.  I25, B34, and O99 were excluded from the principal diagnosis.  Principal diagnosis I25, 
Chronic ischemic heart disease, B34; Viral infection of unspecified site; and O99; other maternal 
diseases were classifiable elsewhere, but complicating pregnancy, childbirth and the puerperium  
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were excluded in this study.  The category of comorbidity was based on the “principal diagnosis 
+ secondary diagnosis”: no comorbidity, Psych + Med, Psych + Psych, Psych + SUD, SUD + 
Med, and SUD + SUD).  This table was generated from the data collected from 346 patients. 
*One-way ANOVA was conducted to determine if inpatient medication cost was different under 
the subgroups of each variable.   
 
 
 
During the early stages of data collection, we found that individuals had multiple 
secondary ICD-10-CM codes and that one individual had up to 26 secondary ICD-10-CM codes.  
More than 25% of patients (of 391 patients) had more than 10 secondary ICD-10-CM codes.  All 
secondary ICD-10-CM codes were collapsed in order to capture the most expensive secondary 
ICD-10-CM code for each patient.  Table 3.2 depicts the process of generating one secondary 
ICD-10-CM code for each patient. The five-code condensing process follows.   
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Table 3.2 
Secondary ICD-10-CM Codes Condensing Process 
Note.  Three patients contained code Z23, encounter for immunization.  Since it may possibly 
yield the medication expenditure on immunization purchase in the acute psychiatric hospital, the 
code Z23 was retained in the first step for patients with this code.   
 
 
 
In the process of condensing secondary ICD-10-CM codes, codes S, T, W, Y, Z as 
described in Table 3.2 were deleted from all 391 patients with the exception of Z23 (Z23, 
encountered for immunization was identified as a medication cost related code) after following 
steps 1 to 3.  Subsequently, indications were checked by referring to the book: Applied 
Therapeutics: The Clinical Use of Drugs and Food and Drug Administration (FDA) drug insert 
(online) during step 4 and 5 [15][192, 193].  Forty-five of 391 patients were not found to have an 
assigned secondary ICD-10-CM codes (three patients did not have secondary ICD-10-CM codes 
Step Description Criteria 
1 Deleting Code Z Categories Z00-Z99 are provided for occasions when 
circumstances other than a disease, injury or external cause 
classifiable to categories A00-Y89 are recorded as ‘diagnoses’ 
[174]. 
2 Deleting Code V-Y V00-Y99.  Environmental events and circumstances as the cause 
of injury, and other adverse effects [15].   
3 Deleting Code S-T S00-T88.  Injury, poisoning and certain other consequences of 
external causes [15].   
4 Keeping Code under MUC MUC-Chapter 2. 
 1.  Reviewed each patient’s medication consumption list and 
found out the medications listed under the MUC 
 2.  Targeted medications that were not used for the principal 
 ICD-10-CM codes but under MUC 
 3.  Checked those medications’ indications, and then located the 
most matched ICD-10-CM codes [15][192, 193].   
 4.  If  the situation of two matched ICD-10-CM codes existed 
under one patient, the most expensive one was retained and 
recorded as the final secondary ICD-10-CM codes for the 
patients 
5 What if no medications 
under MUC 
The indication of the most costly medications was checked 
[29][193] andthe most matched ICD-10-CM code was then 
located [15].   
 A total of 346 patients with secondary ICD-10-CM code were recorded (all retained 
secondary ICD-10CM-code must be related to medication treatment and contribute to 
medication cost).   
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in the original patient coding and summary report; 42 patients’ secondary ICD-10-CM codes that 
were not found to be related to medication treatment were excluded).  Therefore, the assigned 
secondary ICD-10-CM codes for 346 patients was recorded.  Next, secondary DRGs and 
secondary MDC (SMDC) for a total 346 patients were generated in Table 3.3 using the ICD-10-
CM code and DRGs conversion tool [194, 195].  
 
Table 3.3 
Secondary Major Diagnostic Categories SMDC and Diagnosis Related Groups ( DRGs) 
Mapping in this Study 
SMDC 
No. 
SMDC (DRGs Range) Secondary DRGs 
(frequency) 
Total 
Frequency 
23 Factors Influencing Health Status and 
Other Contacts with Health Services 
(939-951) 
951 (68) 68 
19 Mental Diseases and Disorders (876-887) 880 (10), 881 (4), 882 (12), 
883 (14), 884 (1), 885 (13), 
886 (1), 887 (1) 
56 
10 Endocrine, Nutritional and Metabolic 
System (614-645) 
638 (1), 639 (22), 641 (1), 
642 (18), 645 (11) 
53 
05 Circulatory System (215-316) 293 (1), 303 (4), 305 (30), 
310 (6), 316 (1) 
42 
04 Respiratory System (163-208) 192 (12), 201 (3), 203 (18) 33 
20 Alcohol/Drug Use or Induced Mental 
Disorders (984-897) 
897 (31) 31 
01 Nervous System (020-103) 057 (1), 060 (1), 074 (2), 
093 (9), 101 (4), 103 (1) 
18 
08 Musculoskeletal System and Connective 
Tissue (453-566) 
546 (1), 547 (1), 552 (4), 
554 (5), 556 (3) 
14 
11 Kidney and Urinary Tract (652-700) 675 (4), 690 (6), 699 (2), 
700 (2) 
14 
06 Digestive System (326-395) 392 (9) 9 
07 Hepatobiliary System and Pancreas (405-
446) 
434 (2) 2 
09 Skin, Subcutaneous Tissue and Breast 
(573-607) 
603 (1), 607 (1) 2 
02 Eye (113-125) 125 (1) 1 
12 Male Reproductive System (707-730) 726 (1) 1 
13 Female Reproductive System (734-761) 759 (1) 1 
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21 Injuries, Poison and Toxic Effect of 
Drugs (901-923) 
914 (1) 1 
Note.  In total, 346 patients had secondary DRGs.  SMDC was included in the regression 
analysis as a potential contributing factor of inpatient medication cost and LOS.   
 
 
 
3.3.1 Determinants of Inpatient Medication Costs 
A model explaining inpatient medication costs using information from categories of 
predictor variables has been justified using the information from  categories of predictor 
variables listed in equation (1)  
 
cost = f (patient demographics, diagnosis category, comorbidity, LOS, MUC, 
                                               insurance type, month admitted)                                                  (1)                                                               
           
In order to better explain the dependent variable inpatient medication cost, the natural log 
of the medication cost variable was adopted.  During regression analysis, the natural logarithm of 
a variable is commonly used and is a convenient method of transforming a highly skewed 
variable into one that is more approximately normal [196]; Figure 3.1 below illustrates two 
histograms of inpatient medication costs.  The histogram on the left illustrates a positively 
skewed distribution having a value of 3.3608, which implies there is a group of patients bunched 
at lower medication cost.  Under this scenario, the cost data skewed to the right indicates the 
mean of cost is greater than the median of cost.  The histogram on the right depicts how taking a 
log-transformation of the cost variable brings the widely-spread data points from the right tail 
towards the rest of the data. The skewness value of the right histogram is 0.2449 and the 
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distribution looked similar to a normal distribution.  This dependent variable will distribute the 
drug cost more normally. 
 
 
Figure 3.1  Original and natural log transformed cost histogram graph 
 
Therefore, rather than using the actual medication cost as the outcome variable, a linear 
regression is hypothesized between a log transformed outcome variable and a group of predictor 
variables.  This relationship can be shown in the equation (2) 
 
                                          ln (𝑦𝑖) = 𝛽0 + 𝛽1𝑥1𝑖 + ⋯ + 𝛽𝑘𝑥𝑘𝑖 + 𝑒𝑖                                              (2) 
      
where y denotes the outcome variable, medication cost and x1, ⋯, xk are the control variables 
coming from the categories in equation (1).  It is assumed that y is log-normal condition on all 
covariates.  The expected change in ln(y) is interpreted with respect to a one-unit increase in x1 
holding all predictor variables at any fixed value.  Therefore, the inpatient medication cost is 
modelled  by using the information from categories of predictor variables listed in equation (3) 
below:                                            
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ln (cost) = f (patient demographics, diagnosis category, comorbidity, LOS, MUC, 
                           insurance type, and month admitted)                                                               (3)     
 
Table 3.4 identified, defined, and provided summary statistics for the specific variables 
included in the model.  The table also includes the predicted sign when appropriate.  Diagnosis 
and medication treatment attributes denote the set of four variables: comorbidity, principal ICD-
10-CM code, SMDC, and MUC.  Demographics contain two variables.  We included the age of 
patient in order to capture the association between age and the propensity for higher inpatient 
medication expenditures.  It is known that an increasing number of seniors with heart disease, 
diabetes, and other chronic illnesses tend to have mental illness, and may lead to more inpatient 
services, which is inclusive of medication treatment [197].  Demographics also contained an 
indicator of the gender of patients, as evidence has been given to support the correlation between 
this factor and the incidence of mental illness [150].  Insurance type was indicated as private, 
Medicare, uninsured, or dual-eligible (Medicare and Medicaid).  Months admitted indicated 
March, April, May, June, and July. 
 
 
 
 
 
 
 
 
 80 
Table 3.4 
Variable Definition and Summary Statistics for Regression (n = 346) 
Variable Definition Mean 
[S.D.] 
Expected 
Sign 
Outcome variables 
Cost Total cost of four months inpatient medication in 
the acute psychiatric hospital (US $) 
188.352 
[411.689]  
 
lnCost Log transformed of total four months inpatient 
medication cost in the acute psychiatric hospital 
3.665 
[1.822]   
 
LOS Length of stay in acute psychiatric hospital 6.185 
[6.399] 
 
Control variables 
Age Patient age 47.777 
[16.785] 
(+) 
Age2 The square of Age  2563.592 
[1624.023] 
? 
Gender Indicator variable = 1 if patient gender is female, 
0 otherwise 
0.483 
[0.500] 
(?) 
LOS Length of stay in acute psychiatric hospital 6.185 
[6.399] 
(+) 
MUC 
(Medications 
under control) 
Indicator variable = 1 if patient did not take the d 
medication s that included in the 51 medications 
(including 21.77% of total medication units) that 
consumed about 91.43% of 4 months inpatient 
medication costs), 0 otherwise 
0.754 
[0.431] 
(+) 
Comorbidity  Set of 5 binary variables indicating the status of 
comorbidity.  (Psych-Med omitted*) 
0.861 
[0.346] 
(+) 
Principal 
diagnosis (ICD-
10-CM codej) 
Set of 16 binary variables indicating principal 
diagnosis code in which the patient was 
assigned.  (F33. Major depression disorder, 
recurrent omitted*) 
N/A N/A 
Secondary 
Diagnosis 
(SMDCj) 
Set of 16 binary variables indicating secondary 
major diagnostic category in which the patient 
was assigned (Mental Diseases and Disorders 
omitted*) 
N/A N/A 
Admission Monthj Set of 4 binary variables indicating the month in 
which the patient was admitted (June omitted*)  
N/A N/A 
Insurancej Set of 3 binary variables indicating the insurance 
type that patient had during the hospitalization 
(Private omitted*) 
N/A N/A 
Note. omitted variables are also known as reference variables. The results were 
discussed based on the comparison between the reference variable and other variables. 
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LOS is a proxy for the inpatient medication cost, which has not been commonly studied 
in acute psychiatric hospitals.  It captures, albeit imperfectly, the impact of longer hospital days 
on inpatient medication cost.  A number of studies have justified and provided evidence for the 
use of LOS as a proxy for inpatient medication cost [176-179] [185] [186] [187].  Previous 
studies have examined the reasons why count data,  like LOS, can be explained by a count 
outcomes regression model [198][51].  
 The construction of variables that were used in the count outcomes regression (Poisson 
regression) were the same as the variables in the multiple linear regression (medication cost as 
outcome variable) and follows their description.  In particular, we model acute psychiatric 
hospitalization days in equation (4) as a Poisson-distribution since it counts the number of times 
an event occurs in a given period.  The study of hospitalization data demonstrates the statistical 
reasons as to why this type of variable needs to be explained by implementing a count outcome 
regression model [199].   Poisson modeling has been applied to health issues.  To illustrate, 
Poisson modeling was applied to explain the incidence of schizophrenia as well as to study the 
number of days ill in a given month [200, 201].  An appropriate regression model for count data 
often follows a Poisson distribution or one of its variants. One of the rarely met assumptions of a 
Poisson model is that the mean must equal the variance. When the conditional variance is found 
to be greater than the mean, overdispersion may occur [202-204].  An over-dispersed Poisson 
model produces incorrect variance estimates that are biased downwards, which is when a 
negative binomial (NB) model, which does not constrain the conditional variance to equal the 
mean, is preferred over a Poisson model [205]. Our study used both the Poisson and NB 
regression model. 
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We modelled LOS in equation (4) as Poisson-distributed given that it counts the number 
of events (hospital days) in an interval.  
 
LOS = f (patient demographics, diagnosis category, comorbidity, MUC, 
                                               insurance type, and month admitted)                                             (4)           
 
Theoretically, the mean and variance of Poisson-distributed variables are equal [206]; 
however, Table 3.4 shows that the variance of days (40.95 = 6.3992) is more than six times its 
mean (6.185) in our study sample.  This implies a higher dispersion in the predicted number of 
hospital days than what has been allowed by the Poisson distribution.  This indicates that the 
Poisson underestimates the standard errors of the estimated coefficients.  The Poisson estimates 
the expected number of hospital days for the 𝑖th patient, i(X), which is conditional upon the set 
of explanatory variables, X.  By definition, 𝑢𝑖(X) ≡ 𝑒
𝛼+Σ𝑗𝛽𝑗𝑥𝑖𝑗 is the mean number of hospital 
days for 𝑖 given its value for each predictor variable 𝑥𝑖𝑗.  Notably, this definition guarantees that 
the mean number of hospital days is positive.   
The underestimated dispersion is corrected by redefining the expected number of days as 
𝑢𝑖(X) ≡  𝑒
𝛼+Σ𝑗𝛽𝑗𝑥𝑖𝑗+𝜀, which includes the error term,  that allows for unobserved heterogeneity 
beyond what is captured by the set of predictors [207].  Adding  shows that all hospital days are 
negative binomial-distributed, which is a generalization of the Poisson distribution.   
A formal examination for overdispersion is then conducted by comparing the NB 
estimation with the Poisson estimation using a likelihood ratio test.  This likelihood comparison 
is computed as 2 = 2(ln LNB − ln LP) = 2(-887.7870+1035.7035) = 295.833, where LNB and LP 
denote the natural logs of the likelihood functions for the NB and Poisson regressions (see Table 
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3.5).  Therefore, the null hypothesis (no overdispersion) was rejected.  Accordingly, we used a 
NB regression to estimate equation (4) more accurately.  The results of NB estimation are 
depicted. 
 
Table 3.5 
Comparison Between Negative Binomial Regression and Poisson Regression  (Outcome 
Variable: Length of Stay (LOS), n = 346).  Statistically Significant Estimates Are Highlighted 
 
 
 
Variable 
Negative binomial 
(n=346) 
 Poisson (n=346) 
Length of stay (LOS)  Length of stay (LOS) 
Coefficient I.R.R.b 
 
Number 
of 
patients 
Coefficient I.R.R.b 
Robust 
[S.E.]a 
[LOS, 
Mean=6.185] 
 Robust  
[S.E.]a 
[LOS, 
Mean=6.185] 
Comorbidity (Reference group: psych-medi, n=234) 
    No comorbidity 0.3327 
[0.2369] 
1.3947 
[2.4412] 
11 0.2016 
[0.2426] 
1.2234 
[1.3818] 
    Psych-Psych 0.3780* 
[0.1911] 
1.4594 
[2.8412] 
36 0.3144 
[0.2007] 
1.3695 
[2.2853] 
    Psych-Sub 0.3850 
[0.2189] 
1.4696 
[2.9045] 
36 0.4198 
[0.2446] 
1.5216 
[3.2262] 
    Sub-Medi -0.0179 
[-0.0179] 
0.9822 
[-0.1099] 
28 0.0907 
[0.1929] 
1.0950 
[0.5875] 
    Sub-Sub -0.3344 
[-0.3344] 
0.7158 
[-1.7580] 
1 -0.2230 
[0.4307] 
0.8001 
[-1.2363] 
      
SMDC (Reference: 19.  Mental Diseases and Disorders (876-887) (n=56) 
    1.  Nervous 
System (020-103)) 
0.5383* 
[0.2220] 
1.7130 
[4.4102] 
18 0.4374 
[0.2329] 
1.5487 
[3.3935] 
    2.  Eye (113-
125) 
1.0543** 
[0.2493] 
2.8699 
[11.5655] 
1 0.9899** 
[0.2739] 
2.6910 
[10.4587] 
    4.  Respiratory 
System (163-208) 
0.1812 
[0.1991] 
1.1986 
[1.2285] 
33 0.0859 
[0.2094] 
1.0897 
[0.5546] 
    5.  Circulatory 
System (215-316) 
0.3115 
[0.2115] 
1.3654 
[2.2600] 
42 0.2214 
[0.2250] 
1.2479 
[1.5331] 
    6.  Digestive 
System (326-395) 
0.1557 
[0.2293] 
1.1685 
[1.0423] 
9 0.0320 
[0.2411] 
1.0325 
[0.2012] 
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(Table 3.5 Continued) 
    7.  Hepatobiliary 
System and 
Pancreas (405-
446) 
-0.9162** 
[0.2732] 
0.4000 
[-3.7108] 
2 -1.0166** 
[0.2938] 
0.3618 
[-3.9470] 
    8.  
Musculoskeletal 
System and 
Connective Tissue 
(453-566) 
0.2639 
[0.2799] 
1.3020 
[1.8678] 
14 0.1797 
[0.3086] 
1.1968 
[1.2175] 
    9.  Skin, 
Subcutaneous 
Tissue and Breast 
(573-607) 
0.4687* 
[0.2035] 
1.5980 
[3.6984] 
2 0.3828 
[0.2177] 
1.4664 
[2.8845] 
  10.  Endocrine, 
Nutritional and 
Metabolic System 
(614-645) 
0.5193** 
[0.1856] 
1.6808 
[4.2109] 
53 0.4264* 
[0.1974] 
1.5317 
[3.2886] 
  11.  Kidney and 
Urinary Tract 
(652-700) 
0.5074* 
[0.2470] 
1.6609 
[4.0879] 
14 0.4066 
[0.2398] 
1.5017 
[3.1030] 
  12.  Male 
Reproductive 
System (707-730) 
-1.1589** 
[0.2499] 
0.3138 
[-4.2440] 
1 -1.2940** 
[0.2769] 
0.2742 
[-4.4893] 
  13.  Female 
Reproductive 
System (734-761) 
0.0449 
[0.2393] 
1.0459 
[0.2841] 
1 -0.0156 
[0.2499] 
0.9846 
[-0.0956] 
  20.  Alcohol/Drug 
Use or Induced 
Mental Disorders 
(984-897) 
0.1777 
[0.2222] 
1.1945 
[1.2028] 
31 0.0705 
[0.2454] 
1.0731 
[0.4520] 
  21.  Injuries, 
Poison and Toxic 
Effect of Drugs 
(901-923) 
0.2524 
[0.2095] 
1.2871 
[1.7758] 
1 0.1880 
[0.2136] 
1.2069 
[1.2795] 
  23.  Factors 
Influencing Health 
Status and Other 
Contacts  with 
Health Services 
(939-951) 
0.7752** 
[0.2040] 
2.1711 
[7.2431] 
68 0.7104** 
[0.2074] 
2.0347 
[6.3998] 
 
     
ICD-10-CM codes (Reference:  F33.  Major depression disorder, recurrent) (n=96) 
    F03.  
Unspecified 
dementia 
-0.4855** 
[0.1692] 
0.6154 
[-2.3789] 
1 -0.4275* 
[0.1913] 
0.6522 
[-2.1514] 
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    F10.  
Alcohol related 
disorders 
0.0609 
[0.2014] 
1.0628 
[0.3884] 
10 -0.0830 
[0.2328] 
0.9204 
[-0.4925] 
    F11.  Opioid 
related disorders 
-0.1105 
[0.2084] 
0.8954 
[-0.6470] 
6 -0.2577 
[0.2425] 
0.7728 
[-1.4050] 
    F12.  Cannabis 
related disorders 
0.7998** 
[0.2725] 
2.2250 
[7.5767] 
2 0.6787** 
[0.2431] 
1.9713 
[6.0074] 
    F15.  Other 
stimulant related 
disorders 
-0.3862 
[0.2473] 
0.6797 
[-1.9813] 
3 -0.5056 
[0.2793] 
0.6032 
[-2.4545] 
    F19.  Other 
psychoactive 
substance related 
disorders 
0.4558 
[0.7743] 
1.5774 
[3.5712] 
2 0.2007 
0.8141 
1.2223 
[1.3748] 
    F20.  
Schizophrenia 
0.2599 
[0.1461] 
1.2968 
[1.8360] 
64 0.2053 
[0.1694] 
1.2279 
[1.4093] 
    F22.  Persistent 
delusional disorder 
0.8664** 
[0.1817] 
2.3783 
[8.5246] 
1 0.8517** 
[0.1899] 
2.3436 
[8.3102] 
    F23.  Acute and 
transient psychotic 
disorder 
-0.1842 
[0.1652] 
0.8318 
[-1.0406] 
1 -0.1276 
[0.1928] 
0.8802 
[-0.7412] 
    F25.  
Schizoaffective 
disorders 
0.4633** 
[0.1448] 
1.5893 
[3.6451] 
47 0.4409** 
[0.1543] 
1.5541 
[3.4271] 
    F29.  
Unspecified 
nonorganic 
psychosis 
0.3876** 
[0.1408] 
1.4734 
[2.9281] 
24 0.3550* 
[0.1489] 
1.4262 
[2.6361] 
    F31.  Bipolar 
affective disorder 
0.2022 
[0.1236] 
1.2240 
[1.3857] 
83 0.1813 
[0.1398] 
1.1988 
[1.2294] 
    F32.  Major 
depression 
disorder, single 
episode 
-0.1250 
[0.1477] 
0.8825 
[-0.7267] 
12 -0.1425 
[0.1646] 
0.8672 
[-0.8216] 
    F39.  
Unspecified mood 
[affective] disorder  
0.2790 
(p=0.105) 
[0.1720] 
1.3219 
[1.9907] 
1 0.2134 
[0.2076] 
1.2379 
[1.4716] 
    F41.  Other 
anxiety disorders 
0.3299 
[0.2078] 
1.3908 
[2.4172] 
3 0.3557 
[0.2074] 
1.4272 
[2.6425] 
    F60.  Specific 
personality 
disorders 
-0.3907* 
[0.1756] 
0.6766 
[-2.0003] 
1 -0.4474* 
[0.1859] 
0.6393 
[-2.2309] 
 
     
MUC (Reference: 
absent) (n=85) 
0.2982** 
[0.1027] 
1.3474 
[2.1489] 
261 0.3136** 
[0.1104] 
1.3683 
[2.2778] 
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Age  -0.0196 
[0.0124] 
0.9806 
[-0.1200] 
 -0.0166 
[0.0132] 
0.9835 
[-0.1018] 
Age2 (n=346) 0.0003* 
[0.0001] 
1.0003 
[0.0017] 
 0.0002 
[0.0001] 
1.0002 
[0.0015] 
Gender 
(Reference: Male) 
(n=179) 
0.0782 
[0.0937] 
1.0813 
[0.5030] 
167 0.0336 
[0.1116] 
1.0342 
[0.2116] 
      
Insurance (Reference: Private, n=122) 
     Medicare 0.1421 
[0.1041] 
1.1526 
[0.9441] 
206 0.1512 
[0.1192] 
1.1632 
[1.0097] 
     Uninsured 0.6143* 
[0.2697] 
1.8483 
[5.2470] 
2 0.6438* 
[0.2721] 
1.9037 
[5.5892] 
     Dual 0.5380 
[0.4082] 
1.7125 
[4.4070] 
2 0.5772 
[0.3957] 
1.7811 
[4.8311]  
     
Month admitted (Reference: June 135) (n=122) 
  March 1.9793** 
[0.2308] 
7.2379 
[38.5815] 
1 1.9885** 
[0.2385] 
7.3047 
[38.9949] 
  April 0.8247** 
[0.1864] 
2.2812 
[7.9242] 
16 0.8048** 
[0.1798] 
2.2362 
[7.6459] 
  May 0.1592 
[0.1045] 
1.1726 
[1.0675] 
128 0.1833 
[0.1226] 
1.2012 
[1.2445] 
  July -0.1748 
(p=0.107) 
[0.1085] 
0.8397 
[-0.9917] 
79 -0.2121 
[0.1193] 
0.8089 
[-1.1819] 
 
     
Constant 0.8954* 
[0.4032] 
2.4484 
[8.9585] 
 0.9441* 
[0.4308] 
2.5706 
[9.7140] 
Log 
likelihood 
-887.7870 Log likelihood -1035.7035 
p-value <0.05 p-value                <0.05 
Dispersion 2 295.833c Likelihood of ratio 2       591.86d 
Pseudo R2 0.0854  0.2222 
LR chi2 165.79  591.86 
Note.  * Identifies statistical significance at the 5% level; ** identifies statistical significance at 
the 1% level; a Standard error clustered at the patient level;  b Shows the relative impact of a unit 
change in the predictor; c Test H0: no overdispersion; d Test H0: all days of hospitalization is 
Poisson-distributed. 
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3.3.2 Statistical Analysis 
Data were analyzed using the Microsoft Excel spreadsheet (Version 16.20, 2018) and 
Stata, 2017 (Stata Statistical Software: Release 15.  College Station, TX: StataCorp LLC).  
Figures were generated by Stata 15 and GraphPad Prism 8.  The level of statistical significance 
was set at p < 0.01 or  p < 0.05 for all regression analyses. 
 
3.4  Results and Discussion 
 
In this study, different results were obtained for the relationship between inpatient 
medication cost and different principal diagnosis (psychiatric diagnosis), as well as the 
relationship between cost and secondary diagnoses (psychiatric diagnosis and other chronic 
diagnoses).  Demographic factors, comorbidity, insurance type, patient admission month, and 
51medications (MUC) that required strict control were also included as key factors in cost 
regression modeling.  Thus far, analysis of LOS as a proxy for medication cost to identify the 
contributing factors has been sparsely studied in acute psychiatric hospitals.   
 
3.4.1 Outcome Regression 
 
A cost-transformed multiple regression was performed in order to determine the leading 
factors of inpatient medication costs from gender, age, comorbidity, MUC, insurance, month 
admitted, LOS, ICD-10-CM diagnosis codes, as well as secondary major diagnostic categories 
(SMDC). Negative binomial regression was performed to examine if LOS could be used as a 
proxy for cost.  Further results analyses are presented from Table 3.6 to Table 3.13. 
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Table 3.6  
Regression Results – Comorbidity  
Variable  lnCost Length of Stay 
 ln-transformed  
regression (n=346)  
Negative binomial regression (n=346)  
Number 
of  
patients 
Coefficient Coefficient I.R.R. (Incidence Rate 
Ratio)b,1 
 Robust 
[S.E.]a 
Robust 
[S.E.]a 
Extra days2 [LOS, 
Mean=6.185] 
Comorbidity (Reference 
group: Psych + Med, 
n=234) 
        
No comorbidity 11 -0.1390 
[0.5473] 
0.3327 
[0.2369] 
1.3947 
[2.4412] 
    Psych + Psych 36 0.0938 
[0.4075] 
0.3780* 
[0.1911] 
1.4594 
[2.8412]    
    Psych + SUD 36 -0.5853 
[0.7223] 
0.3850 
[0.2189] 
1.4696 
[2.9045]    
    SUD + Med 28 -1.0960* 
[0.4918] 
-0.0179 
[-0.0179] 
0.9822 
[-0.1099] 
    SUD + SUD 1 -0.8923 
[1.1779] 
-0.3344 
[-0.3344] 
0.7158 
[-1.7580] 
Note.  * Identifies statistical significance at the 5% level; ** identifies statistical significance at 
the 1% level; a Standard error clustered at the patient level;  b Shows the relative impact of a unit 
change in the predictor. 
 
 
The negative coefficient for comorbidity in Table 3.6 suggests that the inclusion of SUD 
+ Med is associated with, on average, a 110% decrease in inpatient medication costs as 
compared to a patient with Psych + Med (reference group), holding everything else in the model 
constant.  No significant difference is found in inpatient medication cost between Psych + Med 
and Psych + Psych.  
 
1 I.R.R is incidence rate ratio. It expresses the incident rate as the relative change in the 
dependent variable when patient in the specific subgroup compared to the reference group. 
 
2 Extra days mean additional hospital days yield when patient in the specific subgroup compared 
to the reference group. Under variable comorbidity,  the reference group is Psych + Med. 
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The results also show that patients whose principal and secondary diagnoses are both 
psychiatric disorders have on average  a 45.94% longer LOS, roughly 3 extra days, compared to 
the patients with Psych + Med, holding everything else in the model constant.  This supports the 
theoretical predication that the number of psychiatric conditions is associated with longer LOS. 
Notably, patients with psychiatric conditions may result in a longer LOS. 
 
Table 3.7  
Regression results - Principal Diagnosis 
Variable     lnCost Length of Stay 
ln-transformed 
regression (n=346) 
     Negative binomial 
      regression (n=346) 
Coefficient Coefficient I.R.R. (Incidence Rate 
Ratio)b 
Number 
of patients 
 
Robust 
[S.E.]a 
Robust 
[S.E.]a 
Extra days [LOS, 
Mean=6.185] 
ICD-10-CM codes 
(Reference:  F33. Major 
depression disorder, 
recurrent) (n=96)  
     
 
 F03. Unspecified 
dementia 
1 -0.8047** 
[0.2519] 
-0.4855** 
[0.1692] 
0.6154 
[-2.3789] 
 F10. Alcohol related 
disorders 
10 1.0022* 
[0.4965] 
0.0609 
[0.2014] 
1.0628 
[0.3884] 
 F11. Opioid related 
disorders 
6 1.2483 
[0.6946] 
-0.1105 
[0.2084] 
0.8954 
[-0.6470] 
F12. Cannabis related 
disorders 
2 0.8264 
[0.9537] 
0.7998** 
[0.2725] 
2.2250 
[7.5767] 
 F20. Schizophrenia 64 -0.0464 
[0.2628] 
0.2599 
[0.1461] 
1.2968 
[1.8360] 
F22. Persistent 
delusional disorder 
1 -1.5945** 
[0.3310] 
0.8664** 
[0.1817] 
2.3783 
[8.5246] 
 F23. Acute and 
transient psychotic 
disorder 
1 0.8390* 
[0.3230] 
-0.1842 
[0.1652] 
0.8318 
[-1.0406] 
F25. Schizoaffective 
disorders 
47 0.1509 
[0.2818] 
0.4633** 
[0.1448] 
1.5893 
[3.6451] 
 F29. Unspecified 
nonorganic psychosis 
24 -0.0697 
[0.3136] 
0.3876** 
[0.1408] 
1.4734 
[2.9281] 
F60. Specific personality 
disorders 
1 1.9560** 
[0.2883] 
-0.3907* 
[0.1756] 
0.6766 
[-2.0003] 
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(Table 3.7 Continued) 
Note.  * Identifies statistical significance at the 5% level; ** identifies statistical significance at 
the 1% level; a Standard error clustered at the patient level;  b Shows the relative impact of a unit 
change in the predictor. 
 
 
 
The findings from the regression shown in Table 3.7 suggest that having a principal 
diagnosis of alcohol related disorder (F10) is associated with, on average, a 100%  increase in 
inpatient medication costs, holding everything else in the model constant. 
We find that LOS are a 59% higher, or roughly 4 extra days in patients with 
schizoaffective disorders (F25). A 47% higher LOS, or about 3 extra inpatient days with 
unspecified nonorganic psychosis compared to a patient with major depression disorder was 
observed. 
Although the results show statistically significant differences among unspecified 
dementia (F03), cannabis related disorders (F12), persistent delusional disorder (F22), and 
specific personality disorders (F60) when compared to the reference group, these are not 
practically that significant despite their statistical significance, due to the small sample size. 
According to our findings, principal diagnoses schizoaffective disorder, unspecified 
nonorganic psychosis, and major depression disorder, recurrent are important predictors of LOS 
(refer to Table 3.7).  This moderately supports the similar findings of prior studies conducted in 
hospitals [187]. 
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Table 3.8 
 Regression Results - Secondary Diagnosis (Secondary Major Diagnosis Categories, SMDC) 
Variable    lnCost Length of Stay 
 ln-transformed 
regression 
(n=346) 
Negative binomial 
 Regression 
 (n=346) 
Number of 
patients  
Coefficient Coefficient I.R.R. 
(Incidence Rate 
Ratio)b 
 Robust 
[S.E.]a 
Robust 
[S.E.]a 
Extra days 
[LOS, 
Mean=6.185] 
SMDC (Reference: 19. Mental 
Diseases and Disorders (876-887) 
(n=56)  
  
   
Nervous System (020-103)) 18 0.6884 
[0.5219] 
0.5383* 
[0.2220] 
1.7130 
[4.4102] 
Eye (113-125) 1 3.7810** 
[0.4977] 
1.0543** 
[0.2493] 
2.8699 
[11.5655] 
Respiratory System (163-208) 33 1.5274** 
[0.4331] 
0.1812 
[0.1991] 
1.1986 
[1.2285] 
Circulatory System (215-316) 42 0.8929* 
[0.4197] 
0.3115 
[0.2115] 
1.3654 
[2.2600] 
Hepatobiliary System and Pancreas 
(405-446) 
2 2.2310** 
[0.6786] 
-0.9162** 
[0.2732] 
0.4000 
[-3.7108] 
Skin, Subcutaneous Tissue and 
Breast (573-607) 
2 -0.2199 
[0.4488] 
0.4687* 
[0.2035] 
1.5980 
[3.6984] 
 Endocrine, Nutritional and 
Metabolic System (614-645) 
53 1.3729** 
[0.4292] 
0.5193** 
[0.1856] 
1.6808 
[4.2109] 
Kidney and Urinary Tract (652-
700) 
14 1.1498* 
[0.5516] 
0.5074* 
[0.2470] 
1.6609 
[4.0879] 
 Male Reproductive System (707-
730) 
1 -0.6113 
[0.4798] 
-1.1589** 
[0.2499] 
0.3138 
[-4.2440] 
 Factors Influencing Health Status 
and Other Contacts with Health 
Services (939-951) 
68 0.5039 
[0.4339] 
0.7752** 
[0.2040] 
2.1711 
[7.2431] 
Note.  * Identifies statistical significance at the 5% level; ** identifies statistical significance at 
the 1% level; a Standard error clustered at the patient level;  b Shows the relative impact of a unit 
change in the predictor. 
 
 
 
When considering secondary diagnoses in Table 3.8, the findings indicate that having a 
secondary diagnosis for the respiratory system is associated with, on average, a 153% increase in 
costs, holding everything else in the model constant. Having the secondary diagnosis in the 
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circulatory system is associated with, on average, an 89% increase in costs when everything else 
in the model is held constant. Also, having a secondary diagnosis in endocrine, nutritional and 
metabolic system, and in kidney and urinary tract is, respectively, associated with, on average, a 
137% and a 115% increase in medication costs, holding everything else in the model constant. 
The finding shows that LOS are 71.3% higher, or roughly 4 extra days,  in patients with 
secondary diagnoses in the nervous system. LOS are 68.08% higher, or roughly 4 extra days, in 
patients with secondary diagnosis in the endocrine, nutritional and metabolic systems. LOS are 
66.09% higher, or roughly 4 extra days, in patients with secondary diagnoses in the kidney and 
urinary tract. Also, LOS are 117% higher, or about 7 extra days, in patients with secondary 
diagnosis in having factors influencing health status and other contacts with health services. 
In the category of SMDC, the inclusion of a secondary diagnosis of an eye condition or a 
hepatobiliary system and pancreas condition has been associated with, on average, a 378% and 
223% increase in costs, respectively, holding others constant.  It must be reiterated that there was 
only one patient with an eye condition, while two patients had been diagnosed with hepatobiliary 
system and pancreas conditions.  Mathematically, they are statistically significant.  From these 
results, we can question the practical significance of the coefficient generated from the small 
sample size until a larger sample size is studied.  Therefore, it would be premature to draw the 
conclusion of significant association among these secondary diagnostic groups.  The same 
explanation is also applicable to the variable ICD-10-CM codes (principal diagnosis): 
unspecified dementia (F03), persistent delusional disorder (F22), acute and transient psychotic 
disorder (F23), and specific personality disorders (F60), as well as to the variable month 
admitted in Table 3.13. 
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Table 3.9  
Regression Results – Gender, Age, MUC, and LOS 
Variable   lnCost Length of stay (LOS) 
ln-transformed 
regression 
(n=346) 
Negative binomial 
 regression  
(n=346) 
Coefficient Coefficient I.R.R. (Incidence 
Rate Ratio)b 
Number of 
patients 
 
Robust 
[S.E.]a 
Robust 
[S.E.]a 
Extra days [LOS, 
Mean=6.185] 
Gender (Reference: Male) 
(n=179) 
167 0.0945 
[0.1671] 
0.0782 
[0.0937] 
1.0813 
[0.5030] 
Age (n=346) 346 0.0393 
[0.0272] 
-0.0196 
[0.0124] 
0.9806 
[-0.1200] 
Age2 (n=346) 346 -0.0004 
[0.0003] 
0.0003* 
[0.0001] 
1.0003 
[0.0017] 
MUC (Reference: absent) 
(n=85) 
261 2.0058** 
[0.1835] 
0.2982** 
[0.1027] 
1.3474 
[2.1489] 
LOS (n=346) 346 0.0966** 
[0.0179] 
N/A N/A 
Note.  * Identifies statistical significance at the 5% level; ** identifies statistical significance at 
the 1% level; a Standard error clustered at the patient level;  b Shows the relative impact of a unit 
change in the predictor. 
 
 
 
MUC and LOS are also worth emphasizing. The results from the cost regression in Table 
3.9 indicates that having medications in MUC is associated with, on average, a 201% increase in 
medication costs, holding everything else in the model constant. The extra hospital day is 
associated with 10% higher medication costs.  
The results from negative binomial regression indicate that a patient taking medications 
in MUC have, on average, a 35% longer LOS, or roughly 2 additional hospital days, holding 
everything else in the model constant.  This indicates that taking medications in the MUC list is 
associated with longer LOS compared to patients who do not take medications in MUC. 
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The results also show that gender is not associated with higher impatient medication costs 
in the acute psychiatric hospital studied. The variable Age was squared to better explore if there 
is a non-linear association between this variable and inpatient medication cost and LOS.  The 
result shows that Age was not associated with inpatient medication costs but was associated with 
LOS.  
Table 3.10 illustrates that the average LOS for the 26-35 years of age group is 5.10 days.  
As the patient’s age increases, the average LOS decreases to 2.09 days (35-45 age group) and 
2.53 days  for the (46-55) year age group.  This reduction reflects the change of IRR value within 
the age category in the regression model (Table 3.9).  However, the average LOS of patients 
increases to 3.87 days and 3.58 days in the 56-65 and 66-75 age groups.  It is notable that the 
average LOS increased significantly to 13 days in the age group of 76 and above.  At this point, 
square of age (Age2) was intruoduced into the regression model to help delineate the realtionship 
between Age and LOS.  In Table 3.9, it is observed that Age2  significnatlly (p<0.05) impact 
LOS.    
 
Table 3.10   
Descriptive Statstics of Patient Age 
Age (n=346) Number of patients (n=346) Total LOS Average LOS 
  18-25 47 110.72 2.36 
  26-35 49 249.79 5.10 
  36-45 63 131.82 2.09 
  46-55 48 121.25 2.53 
  56-65 76 294.08 3.87 
  66-75 52 186.10 3.58 
  76 and over 11 143.00 13.00 
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The equation (5) demonstrates that the relationship between patient's age and LOS is U-shaped 
(Figure 3.2).  The graph was generated by GraphPad Prism 8.  The graph shows that when a 
patient’s age is 33, the LOS is the lowest at approximatley a half day.  When the patient is less 
than or equal to 33 years of age, they have shorter length of stays. After the age of 33, the length 
of stay for a patient increases.  It was observed that patients who were 65 years or older were 
likely to be admitted to a mental hospital and stay longer than other age groups in several 
countries [208].  A systematic review showed that while young adults (18-35 years old) do 
experience mental disorders frequently, they do not tend to seek help or hospitalization [209].  
The result is consistent with the findings of our study. 
 
Age and LOS equation: 
Y(LOS) = 0.0003X(Age)2 − 0.0196X(Age) + 0.8954 
                                                     = 0.0003(X − 32.67)2 + 0.5754                                                 (5) 
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Figure 3.2  The relationship between age and LOS 
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Table 3.11 
Regression Results – Insurance Type 
Variable  lnCost Length of stay (LOS) 
 ln-transformed 
regression 
(n=346)  
Negative binomial 
 regression  
(n=346)  
 
Coefficient Coefficient 
I.R.R. (Incidence Rate 
Ratio)b 
Number of 
patients 
  
Robust  
[S.E.]a 
Robust 
[S.E.]a 
Extra days [LOS, 
Mean=6.185] 
Insurance (Reference: 
Private, n=136) 
       
Medicare 206 0.0526 
[0.1897] 
0.1421 
[0.1041] 
1.1526 
[0.9441] 
Uninsured 2 0.1609 
[0.7689] 
0.6143* 
[0.2697] 
1.8483 
[5.2470] 
Dual (Medicare and 
Medicaid) 
2 -0.1631 
[0.4689] 
0.5380 
[0.4082] 
1.7125 
[4.4070] 
Note.  * Identifies statistical significance at the 5% level; ** identifies statistical significance at 
the 1% level; a Standard error clustered at the patient level;  b Shows the relative impact of a unit 
change in the predictor. 
 
 
 
Table 3.12   
Number of ICD-10-CM Codes in Private Insurance and Medicare 
Insurance  ICD-10-CM codes  
Number of 
Patients 
Number of 
codes 
mean Maximum Minimum p value 
Private 136 838 6.16 18 1 <0.05 
Medicare 206 1679 8.15 26 1 
Total 342 2517     
Note.  Independent T-test was run to show the significant difference between private insurance 
and Medicare. 
 
 
 
Statistically significant differences were found in the number of secondary ICD-10-CM 
codes between priavate insurance and Medicare (refer to Table 3.12).  Medicare patients have 
been found to have more ICD-10-CM codes than paitent with private insurance (p<0.05).  
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However,  there were no statistically significant difference on both cost and LOS among patients 
with different insurance types: Medicare, uninsured, and Dual (Medicare and Medicaid), see 
Table 3.11. 
 
Table 3.13  
Regression results – Month Admitted 
Variable  
lnCost Length of stay (LOS) 
 ln-transformed 
regression 
(n=346)  
Negative binomial  
regression  
(n=346)  
 
Coefficient Coefficient 
I.R.R. (Incidence 
Rate Ratio)b 
Number of 
patients 
  
Robust  
[S.E.]a 
Robust 
[S.E.]a 
Extra days [LOS, 
Mean=6.185] 
Month admitted 
(Reference group: 
June, n=122)  
     
      March 1 -2.6068** 
[1.0296] 
1.9793** 
[0.2308] 
7.2379 
[38.5815] 
      April 16 0.2849 
[0.3993] 
0.8247** 
[0.1864] 
2.2812 
[7.9242] 
      May 128 0.1903 
[0.1885] 
0.1592 
[0.1045] 
1.1726 
[1.0675] 
      July 79 0.0636 
[0.2003] 
-0.1748 
[0.1085] 
0.8397 
[-0.9917] 
Note.  * Identifies statistical significance at the 5% level; ** identifies statistical significance at 
the 1% level; a Standard error clustered at the patient level;  b Shows the relative impact of a unit 
change in the predictor. 
 
 
 
In the variable of month admitted, April was associated with, on average, an 82.3% 
increase (7.9 extra days, p<0.05) in LOS, holding everything else in the model constant when 
compare to the month of June.  This result demonstrates that month or season of the year may 
impact hospital stays, although the short time span studied limits generalizability to other time 
periods or hospitals. 
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In the light of the above statistical findings, we demonstrate that the presence of MUC, 
LOS, and comorbidity were associated with higher inpatient medication costs.  In addition, we 
observed that the principal diagnosis code, alcohol related disorders (F10) may contribute toward 
explaining the fluctuation in inpatient medication costs.  Moreover, patients with diseases of the 
respiratory system, circulatory system, endocrine, nutritional and metabolic system, as well as 
kidney and urinary tract may be associated with higher inpatient medication costs.  Other 
predictors such as gender, age, insurance type, and month admitted are statistically associated 
with higher medication costs in the regression model. 
The secondary DRGs associated with higher inpatient medication costs, in comparison to 
the reference group (mental disease and disorder), are shown in Table 3.14.  The most expensive 
secondary DRGs were among four systems: respiratory, endocrine, nutritional and metabolic 
systems, kidney and urinary tract, and circulatory system.  DRG203 (bronchitis & asthma w/o 
cc/mcc), DRG192 (chronic obstructive pulmonary disease w/o cc/mcc, COPD), and DRG 201 
(pneumothorax without cc/mcc) are included in the respiratory system; meanwhile DRG639 
(diabetes w/o cc/mcc), DRG642 (inborn and other disorders of metabolism), DRG645 (endocrine 
disorders w/o cc/mcc), DRG638 (Diabetes w cc), and DRG641 (nutritional & miscellaneous 
metabolic disorders w/o mcc) are included in endocrine, nutritional and metabolic system; on the 
other hand, DRG690 (Kidney & urinary tract infections w/o mcc), DRG675 (other kidney & 
urinary tract procedures w/o cc/mcc), DRG699 (other kidney & urinary tract diagnoses w cc), 
and DRG700 (other kidney and urinary tract diagnoses without cc/mcc) are included in the 
kidney and urinary tract;  similarly, DRG305 (hypertension w/o mcc), DRG310 (cardiac 
arrhythmia & conduction disorders w/o cc/mcc), DRG303 (atherosclerosis w/o mcc), DRG293 
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(heart failure & shock w/o cc/mcc), and DRG316 (other circulatory system diagnoses w/o 
cc/mcc) are included in the circulatory system. 
 
Table 3.14   
The Most Expensive Secondary DRGs 
Ranking Secondary MDC Secondary DRGs Frequency 
1 Respiratory System** 203.  Bronchitis & asthma w/o 
cc/mcc3 
18 
  192.  Chronic obstructive 
pulmonary disease w/o cc/mcc 
12 
201.  Pneumothorax without 
cc/mcc 
3 
2 Endocrine, nutritional and 
metabolic system** 
639.  Diabetes w/o cc/mcc 22 
 642.  Inborn and other disorders 
of metabolism 
18 
645.  Endocrine disorders w/o 
cc/mcc 
11 
638.  Diabetes w cc 1 
641.  Nutritional & 
miscellaneous metabolic 
disorders w/o mcc 
1 
3 Kidney and urinary tract* 690.  Kidney & urinary tract 
infections w/o mcc 
6 
  675.  Other kidney & urinary 
tract procedures w/o cc/mcc 
4 
  699.  Other kidney & urinary 
tract diagnoses w cc 
2 
  700.  Other kidney and urinary 
tract diagnoses without cc/mcc 
2 
4 Circulatory system* 305.Hypertension w/o mcc 30 
  310.  Cardiac arrhythmia & 
conduction disorders w/o cc/mcc 
6 
  303.Atherosclerosis w/o mcc 4 
  293.  Heart failure & shock w/o 
cc/mcc 
1 
  316.  Other circulatory system 
diagnoses w/o cc/mcc 
1 
 
3 A complication or comorbidity (CC) or a major complication or comorbidity (MCC) when used 
as a secondary diagnosis 
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(Table 3.14 Continued) 
Note.  * Identifies statistical significance at the 5% level; ** identifies statistical significance at 
the 1% level. 
 
 
 
Table 3.15 shows that the secondary MDC (Factors Influencing Health Status and Other Contact 
with Health Services > Nervous System >  Endocrine, Nutritional and Metabolic System > 
Kidney and Urinary Tract > Mental Diseases and Disorders) was also a key predictor of LOS.  
Meanwhile the secondary DRGs associated with longer LOS are listed in Table 3.15. 
 
Table 3.15   
The Longest LOS Secondary DRGs  
Ranking Secondary MDC Secondary DRGs Frequency 
1 Factors Influencing Health 
Status and Other Contact with 
Health Services** 
951.  Other factors 
influencing health status 
68 
2 Nervous System* 093.  Other disorders of 
nervous system w/o cc/mcc 
9 
101.  Seizures w/o mcc 4 
074.  Cranial & peripheral 
nerve disorders w/o mcc 
2 
125.  Other disorders of the 
eye w/o mcc 
1 
057.  Degenerative nervous 
system disorders w/o mcc 
1 
060.  Multiple sclerosis & 
cerebellar ataxia w/o 
cc/mcc 
1 
103.  Headaches w/o mcc 1 
3 Endocrine, Nutritional and 
Metabolic System** 
639.  Diabetes w/o cc/mcc 22 
642.  Inborn and other 
disorders of metabolism 
18 
645.  Endocrine disorders 
w/o cc/mcc 
11 
638.  Diabetes w cc 1 
641.  Nutritional & 
miscellaneous metabolic 
disorders w/o mcc 
 
1 
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(Table 3.15 Continued) 
4 Kidney and Urinary Tract* 690.  Kidney & urinary 
tract infections w/o mcc 
6 
  
675.  Other kidney & 
urinary tract procedures 
w/o cc/mcc 
4 
699.  Other kidney & 
urinary tract diagnoses w 
cc 
2 
700.  Other kidney and 
urinary tract diagnoses 
without cc/mcc 
2 
10  Mental Diseases and 
Disorders 
883.  Disorders of 
personality and impulse 
control 
14 
885.  Psychoses 13 
882.  Neuroses except 
depressive 
12 
880.  Acute adjustment 
reaction and psychosocial 
dysfunction 
10 
881.  Depressive neuroses 4 
884.  Organic disturbances 
and mental retardation 
1 
886.  Organic disturbances 
and mental retardation 
1 
887.  Other mental disorder 
diagnoses 
1 
Note.  * Identifies statistical significance at the 5% level; ** identifies statistical significance at 
the 1% level. 
 
 
 
In most hopsitals, cost contaiment efforts have focused on interventions that reduce LOS 
as a way to reduce the cost of inpatient medications [210]. The results show that the leading 
factors are not the same between two different regression models.  Patients with dieases in 
endocrine, nutritional and metabolic system as well as kidney and urinary tract are signifcantlly 
associated with both higher inpaitent medication cost and longer LOS as comapred to the 
reference group, mental diseases and disorders.   
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In addition, we found that patients who take medications in MUC are associated with 
both higher inpaitent medication cost and longer LOS.  Our findings does not show any 
realtionship between insurance and cost or between insurance and LOS.  
We also recognize that inpaitent medication costs in acute psychiatirc hospitals do not 
occur in a linear ralationship over the lenth of hospital stays.  Shortened LOS may help lower 
inpaitent medication costs to some extent, but they will not be signiicantly impacted by 
eliminaing the last couple of days from a given admission due to the high number of medications 
taken early on  in the admisson [210].   
 
3.5  Conclusion and Limitations 
 
This study uses patient demographic and diagnostic data, medication usage and cost data, 
as well as data of insurance type and admission month from a single acute psychiatric hospital in 
order to identify multiple relationships between the potential leading factors and inpatient 
medication costs.  In this regard, LOS was applied as a proxy to indicate the possible leading 
factors. 
In this study, we found several statistically significant correlations between patient 
diagnosis and inpatient medication cost, but there is one that is distinguished from the others.  
The association of MUC with inpatient medication cost is higher than any other factors. The 
estimates are robust across different models, including the count model (negative binomial 
regression) which uses LOS as a proxy for cost.  However, this finding is not surprising and 
supports the results from the ABC-VEN matric analysis carried out in Chapter 2.  Our findings 
also show that LOS is associated with higher inpatient medication costs. 
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Comorbidity appears to have an impact on higher medication cost when patients 
experience their first diagnosis of a psychiatric disorder and secondary diagnosis with another 
chronic disorder or other psychiatric disorder.  In addition, patients with the secondary diagnosis 
in respiratory system, circulatory systems, endocrine, nutritional and metabolic system, as well 
as kidney and urinary tract are associated with higher inpatient medication costs than the 
reference group - patients with mental disease and disorders.  Under principal diagnosis, patients 
with alcohol related disorder have higher medication cost when compared to the reference group 
- major depression disorder, recurrent. 
When LOS is used as a proxy for inpatient medication costs, our findings demonstrate the 
impact of comorbidity on longer LOS.  A diagnosis of psych-psych is associated with long LOS 
as compared to psych-medi group.  Meanwhile patients with disorders in the nervous system, 
nutritional and metabolic systems, kidney and urinary tract as secondary diagnoses, along with 
factors influencing health status and other contacts with health services, are associated with 
longer LOS as compared to those with mental disorders.  Under principal diagnosis, patient with 
schizoaffective disorders, unspecified nonorganic psychosis, and bipolar affective disorder are 
found to have a correlation with longer LOS as compared to the reference group - major 
depression disorder, recurrent.  Furthermore, young adults (age 18-35) and the elderly (age 65 
and above) are associated with longer LOS.  Under the existing medical system in the United 
States, increasing medication costs are imposing a major financial burden on hospital budgets.  
Identifying the most expensive diagnoses may help with preparing for inpatient medication 
budget.   
In this context, our study revealed that ICD-10-CM code F10 (Alcohol related disorders) 
were associated with higher inpatient medication costs.  Meanwhile with secondary diagnosis, 
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DRG 203 (bronchitis & asthma w/o cc/mcc), DRG 192 (chronic obstructive pulmonary disease 
w/o cc/mcc, COPD), DRG 201 (pneumothorax without cc/mcc), DRG639 (diabetes w/o cc/mcc), 
DRG 642 (inborn and other disorders of metabolism), DRG 645 (endocrine disorders w/o 
cc/mcc), DRG 638 (diabetes w cc), DRG 641 (nutritional & miscellaneous metabolic disorders 
w/o mcc), DRG 690 (kidney & urinary tract infections w/o mcc), DRG675 (other kidney & 
urinary tract procedures w/o cc/mcc), DRG 699 (other kidney & urinary tract diagnoses w cc),  
DRG 700 (other kidney and urinary tract diagnoses without cc/mcc), DRG 305 (hypertension 
w/o mcc), DRG 310 (cardiac arrhythmia & conduction disorders w/o cc/mcc), DRG 303 
(atherosclerosis w/o mcc), DRG 293 (heart failure & shock w/o cc/mcc), as well as DRG 316 
(other circulatory system diagnoses w/o cc/mcc) are linked to higher inpatient medication costs. 
Our study also found that ICD-10-CM codes F25 (schizoaffective disorders), F29 
(unspecified nonorganic psychosis), F31 (bipolar affective disorder), and F33 (major depression 
disorder, recurrent) are the four principal diagnoses that are found to have a strong correlation 
with longer LOS.   Moreover, DRG 951 (other factors that influence health status), DRG 639 
(diabetes /o cc/mcc), DRG 690 (kidney & urinary tract infections w/o mcc), DRG 883 (disorders 
of personality and impulse control), DRG 305 (hypertension w/o mcc), DRG 554 (bone diseases 
& arteriopathies w/o mcc), DRG 203 (Bronchitis & asthma w/o cc/mcc), DRG 897 (alcohol/drug 
abuse or dependence w/o rehabilitation therapy w/o mcc), as well as DRG 392 (esophagitis, 
gastroenteritis and miscellaneous disorders w/o mcc) are the nine secondary DRGs that make a 
significant contribution to longer LOS.   
Toward this end, our work can serve as a useful guide during the formulation of inpatient 
medication budgets.  However, this study did have some limitations that must be addressed.  
First, the analysis of predictors correlating with the cost of inpatient medication and LOS was 
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based on data sourced from a single acute psychiatric hospital.  This, in turn, raises the issue of 
limited generalizability, as study results may potentially incorporate local patient characteristics. 
Thus, the results of this study are not considered generalizable.  There are also differences in the 
admission process and treatment plans between hospitals.  Meanwhile it is important to gather 
and analyze data from multiple acute psychiatric hospitals.  Second, the original sample size (400 
patients) was relatively large in terms of the care provided.  In this study, 346 patients and 2140 
episodes (days of total hospitalization) crossing all main diagnosis groups were included in the 
regression models.  However, the small sample size (one or two patients) for the specific groups 
under every variable was a concern.  However, this issue can be addressed in future studies.  
Increasing the number of participating research hospitals could help resolve the issue of small 
sample size, thereby increasing the validity of the regression models. 
Despite these limitations, this study analyzed the inpatient mediation costs and LOS 
based on data including all patients who had enrolled from the data collection period, as opposed 
to some specific patients restricted to specific diagnostic groups.  Importantly, this study 
analyzed possible factors correlating with increasing inpatient medication costs and longer LOS.  
LOS may be an important contributor to increased hospital expenditures.  Reduced number of 
inpatient days has been shown to be associated with increased hospital profits, improved 
treatment quality, and decreased risk of infection and medication side effects [211].  
Additionally, a longer LOS may increase the possiblitiy of a hospital-acquired condition (HAC), 
which, in turn, may harm patients and lead to an even longer and costlier stay [212].  
Viewed collectively, considering the high cost of medications in hospitals among 
populations with MBDs, this study aimed to make a significant contribution to the existing 
knowledge of cost management and inpatient medication budget in acute psychiatric hospitals.  
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This study would be helpful for the various relevant stakeholders, including mental and 
behavioral health hospitals, MBDs patients, payers (Medicare, Medicaid, insurance companies), 
and policymakers on identifying the leading factors of increased medication costs in acute 
psychiatric hospitals, as well as costs containment strategies and the future trend in medication 
spending in psychiatric hospital-based pharmacies.   
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CHAPTER 4: CONCLUSION AND INNOVATION 
Prices for both commonly and infrequently used medications are spiraling up much faster 
than bundled reimbursements can keep pace with under the existing Medicare reimbursement 
system.  For this reason, hospital medication expenditures are rising at a rapid pace.  In addition, 
medication cost is threatening to inflate hospital operating budgets.  Under these circumstances, 
it is important to control and accurately predict hospital medication budgets.  Against this 
backdrop, the present study is the first one to examine both inpatient medication usage patterns 
and costs, including the medications prescribed for the treatment of mental and behavioral 
disorders, as well as the treatment of chronic diseases in an acute psychiatric hospital.  
In medical hospitals, many studies revealed the starting point for lowering future drug 
spending, such as prescribing generic drugs to lower cost, reducing expenditures for an 
expensive drug class by consolidating to a preferred therapeutic drug, as well as reducing the unit 
cost of drugs via the pharmacy's drug wholesaler or group-purchasing organization (GPO) [5, 21, 
213-218].  An inpatient medication report showed that average inpatient drug expenditures 
increased approximately 40% on a per admission basis from 2013 to 2015 [1].  However, other 
factors that may contribute to increased costs need to be taken into consideration.  For instance, 
the Centers for Medicare and Medicaid Services (CMS) only update the prices paid by them 
every five to seven years for existing medications.  Costs may rise faster than revisions are made.    
With ever-increasing pharmaceutical costs and decreasing hospital drug reimbursement 
rates [137], pinpointing the most expensive medications and diagnoses will allow hospitals to 
develop an optimized budget plan that in turn may enable them to mitigate escalating hospital 
medication costs.  This dissertation research comprises two parts: drug formulary management 
study (Chapter 2); and the leading drivers regression study (Chapter 3), which was conducted 
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based on extensive and comprehensive literature review.  In chapter 2, we demonstrated that 
combined ABC and VEN analysis may enable policymakers in acute psychiatric hospitals to 
focus on the MUC (Medications under control) as one cost-control strategy.  To that end, 51of 
the most expensive medications were explored by the modified ABC-VEN matrix analysis.  
Findings of this study suggest that a study of drug formulary management will help provide 
accurate cost-related statistics to identify and prioritize medications.  A high-priority list (MUC) 
was developed, and this list comprised approximately 90% of four-month inpatient medication 
expenditures, which implies 90% of total medication expenditures for the following quarter 
could likely to be budgeted for.   
The research conducted in chapter 3 can potentially fill the existing gap in understanding 
medication usage and expenses for patients with mental and behavioral disorders (MBD) in acute 
psychiatric hospitals.  However, more importantly, it may have an impact on the reasonable 
development of hospital pharmacy budgets by analyzing a variety of contributing factors 
including patient demographics, diagnostic category, length of stay (LOS), medications under 
control (MUC), insurance type, as well as month admitted.  
Our results indicate that patients with a principal diagnosis code F10 (alcohol related 
disorders) had a significant impact on the inpatient medication cost, but not LOS.   F25 
(schizoaffective disorders), and F29 (unspecified nonorganic psychosis) are strongly associated 
with longer LOS, but not inpatient medication cost.  Additionally, no principal diagnosis code is 
associated with both longer LOS and higher inpatient medication cost. Even though there were 
no differences by psych diagnoses, these were high volume and thus in total a high cost class of 
agents.  If pharmacy managers can look within that group to possibly narrow the medications 
included on a formulary to one focusing on medications with the best price and efficacy, then 
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medication costs may be reduced. Also, exploring the potential to limit the use of high-cost non-
formulary agents particularly new agents that offer no known advantage over existing ones may 
be useful. 
Secondary DRGs under the respiratory system include DRG 203 (bronchitis & asthma 
w/o cc/mcc), DRG 192 (chronic obstructive pulmonary disease w/o cc/mcc), DRG 201 
(pneumothorax without cc/mcc); as well as under endocrine, nutritional and metabolic system 
include DRG 639 (it is also inclusive of diabetes w/o cc/mcc), DRG 642 (inborn and other 
disorders of metabolism), DRG 645 (endocrine disorders w/o cc/mcc), DRG 638 (diabetes w cc), 
DRG 641(nutritional & miscellaneous metabolic disorders w/o mcc), and DRG 690 (kidney and 
urinary tract).  Meanwhile other kidney and urinary tract infections in the following DRGs: DRG 
675 (other kidney & urinary tract procedures w/o cc/mcc), DRG 699 (other kidney and urinary 
tract diagnoses w cc), DRG 700 (other kidney and urinary tract diagnoses without cc/mcc) are 
the most expensive DRGs that have a significant impact on the inpatient drug cost.  Among 
these, DRG 639 (diabetes w/o cc/mcc) and DRG 690 (kidney & urinary tract infections w/o mcc) 
are the two secondary DRGs that associated with higher inpatient medication cost and longer 
LOS.  Therefore, policymakers and administrators should consider the impact of patients with 
these secondary DRGs being admitted when developing medication budgets.  In this regard, 
strategies to reduce medication costs for these conditions (diabetes, kidney diseases, asthma, 
COPD, hypertension ) include formulary review to select/consolidate the number of agents 
within classes (e.g. ACEIs, inhalers), leverage the policy on therapeutic substitution to preferred 
agents, or leverage the ability to use home medications. 
Patients with comorbid psychiatric disorders (psych-psych) may lead to a longer LOS.  In 
this study, patients admitted in April stayed in the hospital for a longer time in comparison to 
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July indicating that there may be seasonal variations in LOS.  This would require further study to 
determine its importance.  No LOS difference was found between patients with various insurance 
types.  We found that the number of secondary ICD-10-CM codes varied between patients with 
private insurance and Medicare.  However, medication costs did not differ.  Patient in age groups 
between 18-35 and 56-75 potentially have a longer LOS as compared to other age groups.  
Among the many influencing factors, MUC merits the most attention.  It affects both inpatient 
drug cost and LOS within the acute psychiatric hospital.  Thus, more efforts should put to control 
and manage medications on this list. 
Hospital pharmacy data are powerful tools that can help regulate and lower medication 
expenditures.  In addition to drug cost, measuring all feasible healthcare data is an important 
method in studying the reasons for increasing medication expenditures.  Rather than merely 
investigating drug cost per patient, focusing on drug cost per DRGs (diagnosis-related groups) 
allows the alignment of expense analysis by reimbursement groups.  It is important to consider 
the LOS and other similar measures that reflect the overall drug costs [10].  For this reason, 
identifying drug cost saving through utilization-based data is imperative.   
Using a systemic analysis of drug costs and usage patterns in an acute psychiatric 
hospital, one can determine whether medication costs are related more to psychiatric conditions 
or other medical conditions, or a combination of them.  This, in turn, could be important 
information for administrators when negotiating contracts to care for patients if the 
characteristics of the patient population are known.  Notably, this was a study in a unique 
environment (acute psychiatric hospital) where very little is known about the cost drivers of all 
medications prescribed in that setting.  This study demonstrates the need for exploration of cost 
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drivers for a particular acute psychiatric hospital as a means of better forecasting medication 
expenditures within that setting, so as to develop a more accurate pharmacy budget.   
This study entailed several innovative aspects.  One of the major strengths is that we 
measured and examined the inpatient medication usage patterns as well as costs, including the 
drugs prescribed for MBDs treatment and chronic disease treatments within a mental and 
behavior inpatient setting.  It is among the few studies to implement ABC-VEN matrix analysis 
to MBDs patients, specifically in a psychiatric hospital.  Second, one of the strengths of this 
research is that we generated the secondary DRGs for admitted patients by reprogramming the 
ICD-10 codes.  Additionally, we make use of prediction models to identify the most important 
factors associated with high inpatient drug cost and longer LOS. 
The findings of this study will allow the executives of an acute psychiatric hospital to 
identify the most important factors associated with high inpatient medication costs by applying 
the cost prediction model.  This implies that the management of hospital pharmacy budget could 
be improved by an approach rooted in scientific research.  Future studies should be focused on 
patient data collected from multiple psychiatric hospitals.  Overcoming the challenge of 
relatively a small patients sample size will help better target drivers of increasing inpatient 
medication cost.  
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